[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2097
1. le Coutre P, Meisel H, Hofmann J, Röcken C, Vuong GL, Neuburger S, Hemmati PG, Dörken B, Arnold R: Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut; 2009 May;58(5):699-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation.
  • Here, an indigenous acute limited hepatitis E in a patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia prior to allogeneic stem cell transplantation is reported.
  • [MeSH-major] Hepatitis E / etiology. Hepatitis E virus / isolation & purification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Adult. Animals. DNA, Viral. Humans. Immunocompromised Host. Male. Meat Products / virology. Philadelphia Chromosome. RNA, Viral. Recurrence. Swine

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Hepatitis E.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19359434.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / RNA, Viral
  •  go-up   go-down


2. Couto E, Chen B, Hemminki K: Association of childhood acute lymphoblastic leukaemia with cancers in family members. Br J Cancer; 2005 Nov 28;93(11):1307-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of childhood acute lymphoblastic leukaemia with cancers in family members.
  • Children whose twins have had leukaemia have a higher risk of contracting acute lymphoblastic leukaemia (ALL), confirming a prenatal origin of the disease.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cohort Studies. Female. Humans. Incidence. Male. Middle Aged. Pedigree. Sweden / epidemiology. Testicular Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1999 Oct 30;354(9189):1499-503 [10551495.001]
  • [Cites] BMJ. 2005 Jun 4;330(7503):1294 [15849205.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):388-91 [11161404.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):990-3 [11286482.001]
  • [Cites] Lancet. 2001 Sep 1;358(9283):711-7 [11551577.001]
  • [Cites] Acta Oncol. 2001;40(6):772-7 [11765074.001]
  • [Cites] Cancer Causes Control. 2001 Dec;12(10):935-41 [11808713.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2321-33 [12791663.001]
  • [Cites] Cancer Detect Prev. 2004;28(2):83-7 [15068830.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6429-44 [15322515.001]
  • [Cites] Lancet. 1990 Sep 8;336(8715):577-82 [1975376.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 4;84(5):306-12 [1738180.001]
  • [Cites] Am J Epidemiol. 1992 Oct 15;136(8):916-24 [1456268.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):1-5 [7819022.001]
  • [Cites] Med Pediatr Oncol. 1996 Apr;26(4):223-9 [8600332.001]
  • [Cites] Lancet. 1997 Feb 1;349(9048):344-9 [9024390.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(14):1941-53 [10711237.001]
  • (PMID = 16288301.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Twin Study
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361521
  •  go-up   go-down


3. Bieber MM, Twist CJ, Bhat NM, Teng NN: Effects of human monoclonal antibody 216 on B-progenitor acute lymphoblastic leukemia in vitro. Pediatr Blood Cancer; 2007 Apr;48(4):380-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of human monoclonal antibody 216 on B-progenitor acute lymphoblastic leukemia in vitro.
  • This study investigated if this mAb could bind and kill acute lymphoblastic leukemia (ALL) B-progenitor lymphoblasts in vitro.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antineoplastic Agents / pharmacology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Acute Disease. Adult. Bone Marrow / immunology. Bone Marrow / pathology. Cell Line, Tumor / drug effects. Cell Line, Tumor / immunology. Child. Complement System Proteins / immunology. Drug Screening Assays, Antitumor. Hematopoietic Stem Cells / drug effects. Hematopoietic Stem Cells / immunology. Humans. Immunophenotyping. Immunotherapy. Leukemia, Myeloid / immunology. Leukemia, Myeloid / pathology. Leukemia-Lymphoma, Adult T-Cell / immunology. Leukemia-Lymphoma, Adult T-Cell / pathology. Neoplastic Stem Cells / drug effects. Neoplastic Stem Cells / immunology. Specimen Handling. Tissue Preservation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16421902.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 98543
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 9007-36-7 / Complement System Proteins
  •  go-up   go-down


Advertisement
4. Brouwer CA, Gietema JA, van den Berg MP, Bink-Boelkens MT, Elzenga NJ, Haaksma J, Kamps WA, Vonk JM, Postma A: Low-dose anthracyclines in childhood Acute Lymphoblastic Leukemia (ALL): no cardiac deterioration more than 20 years post-treatment. J Cancer Surviv; 2007 Dec;1(4):255-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose anthracyclines in childhood Acute Lymphoblastic Leukemia (ALL): no cardiac deterioration more than 20 years post-treatment.
  • [MeSH-major] Anthracyclines / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Daunorubicin / therapeutic use. Heart Function Tests. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cross-Sectional Studies. Female. Follow-Up Studies. Humans. Male. Survivors. Time Factors


5. He S, Guo Y, Bei CF, Dai YZ, Zhu DB, Li CS, Zhu XH, LE MZ: [Gastrointestinal B-cell lymphoma: a morphologic and immunohistochemical study of 194 cases]. Zhonghua Bing Li Xue Za Zhi; 2010 Dec;39(12):814-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointestinal B-cell lymphoma: a morphologic and immunohistochemical study of 194 cases].
  • METHODS: One hundred and ninety-four cases of gastrointestinal B-cell lymphoma were retrieved from the archival file.
  • Amongst the 194 cases studied, 128 (66.0%) were diagnosed as diffuse large B-cell lymphoma, including 16 cases of large cell lymphoma associated with mucosa-associated lymphoid tissue (MALT) lymphoma component.
  • There were also 40 cases (20.6%) of MALT lymphoma, 8 cases (4.1%) of follicular lymphoma, 5 cases of (2.6%) of lymphoplasmacytic lymphoma, 3 cases (1.6%) of mantle cell lymphoma, 1 case of (0.5%) of B-lymphoblastic lymphoma and 9 cases (4.6%) of indefinite type (including 5 biopsy cases).
  • The lymphoma cells in all cases were immunoreactive for B-cell marker CD20.
  • [MeSH-major] Antigens, CD20 / metabolism. Gastrointestinal Neoplasms / metabolism. Gastrointestinal Neoplasms / pathology. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. DNA-Binding Proteins / metabolism. Female. Humans. Immunohistochemistry. Lymphoma, B-Cell, Marginal Zone / metabolism. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / surgery. Lymphoma, Follicular / metabolism. Lymphoma, Follicular / pathology. Lymphoma, Follicular / surgery. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / surgery. Male. Middle Aged. Neoplasm Invasiveness. Neprilysin / metabolism. Young Adult

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21215096.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


6. van Imhoff GW, van der Holt B, MacKenzie MA, Ossenkoppele GJ, Wijermans PW, Kramer MH, van 't Veer MB, Schouten HC, van Marwijk Kooy M, van Oers MH, Raemaekers JM, Sonneveld P, Meulendijks LA, Kluin PM, Kluin-Nelemans HC, Verdonck LF, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON): Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia; 2005 Jun;19(6):945-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
  • The feasibility and efficacy of up-front high-dose sequential chemotherapy followed by autologous stem cell transplantation (ASCT) in previously untreated adults (median age 33 years; range 15-64) with Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or lymphoblastic lymphoma (LyLy), both without central nervous system or extensive bone marrow involvement was investigated in a multicenter phase II study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Burkitt Lymphoma / drug therapy. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / adverse effects. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Follow-Up Studies. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Prednisone / administration & dosage. Prednisone / adverse effects. Transplantation, Autologous

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800666.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone
  •  go-up   go-down


7. Djokic M, Björklund E, Blennow E, Mazur J, Söderhäll S, Porwit A: Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia. Haematologica; 2009 Jul;94(7):1016-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia.
  • We evaluated CD123 expression in 95 pediatric and 24 adult ALL patients and compared the results with the CD123 expression in normal B-cell precursors.
  • Leukemic blasts in 31% of precursor-B ALL samples exhibited strong expression of CD123, 61% had moderate CD123 expression and 8% were negative; 81.5% of ALL with hyperdiploid karyotype (>/= 52 chromosomes) showed strong CD123 overexpression.
  • Our study suggests that overexpression of CD123 is an aberrant phenotype present in a subset of precursor-B ALL with hyperdiploid genotype, and represents an additional marker of good prognosis in pediatric precursor-B ALL.
  • [MeSH-major] Diploidy. Gene Expression Regulation, Leukemic. Interleukin-3 Receptor alpha Subunit / biosynthesis. Interleukin-3 Receptor alpha Subunit / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Child, Preschool. Genotype. Humans. Infant. Infant, Newborn. Karyotyping. Middle Aged. Phenotype

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Mar;14(3):403-11 [10720134.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1908-10 [16900212.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4634-7 [12036900.001]
  • [Cites] Leukemia. 2003 Jan;17(1):138-48 [12529671.001]
  • [Cites] Leukemia. 2004 Feb;18(2):219-26 [14671644.001]
  • [Cites] Blood. 1989 Feb;73(2):533-42 [2644978.001]
  • [Cites] Annu Rev Immunol. 1992;10:295-331 [1590989.001]
  • [Cites] Blood. 1993 Jul 1;82(1):22-8 [8100720.001]
  • [Cites] Blood. 1996 Jan 1;87(1):112-22 [8547632.001]
  • [Cites] Leukemia. 1999 Mar;13(3):419-27 [10086733.001]
  • [Cites] Med Pediatr Oncol. 1999 May;32(5):360-5 [10219338.001]
  • [Cites] Leukemia. 1999 Aug;13(8):1109-66 [10450743.001]
  • [Cites] Leukemia. 2005 Jan;19(1):49-56 [15538405.001]
  • [Cites] Immunol Lett. 2005 Apr 15;98(1):9-21 [15790504.001]
  • [Cites] Eur J Haematol. 2005 Jun;74(6):466-80 [15876250.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2527-9 [15928038.001]
  • [Cites] Haematologica. 2001 Dec;86(12):1261-9 [11726317.001]
  • (PMID = 19454491.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Interleukin-3 Receptor alpha Subunit
  • [Other-IDs] NLM/ PMC2704314
  •  go-up   go-down


8. Müller-Beissenhirtz H, Kasper C, Nückel H, Dührsen U: Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study. Ann Hematol; 2005 Nov;84(12):796-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study.
  • Diagnoses included B lymphoblastic (n=1), diffuse large B cell (n=10), anaplastic large T cell (n=2) and peripheral T-cell NHL (n=2).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. Humans. Infection / etiology. Infection / mortality. Leukopenia / etiology. Leukopenia / mortality. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / adverse effects. Prospective Studies. Recurrence. Remission Induction. Thrombocytopenia / etiology. Thrombocytopenia / mortality. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives

  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16041531.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine; VB0R961HZT / Prednisone
  •  go-up   go-down


9. El-Sissy A, El-Mashari M, Bassuni W, El-Swaayed A: Molecular detection of BCR/ABL fusion gene in Saudi acute lymphoblastic leukemia patients. J Egypt Natl Canc Inst; 2006 Jun;18(2):109-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular detection of BCR/ABL fusion gene in Saudi acute lymphoblastic leukemia patients.
  • A fraction of acute lymphoblastic leukemia (ALL) cases carry the translocation t(9;22) (q34;q11.2) which juxtaposes the ABL proto-oncogene to the BCR gene generating a chimeric gene, BCR/ABL.
  • This aberration is more frequent in adult ALL (20%-40%) than in pediatric ALL (<5%), and predicts poor clinical outcome.
  • PATIENTS AND METHODS: Twenty newly diagnosed ALL patients, 16 adult and 4 paediatric cases, were included in the study, 11 cases (55%) were of precursor B phenotype, 8 cases (40%) belonged to T lineage, while one case was biphenotypic expressing mainly precursor B cell markers tether with CD13, CD33, CD117, Detection of BCR/ABL fusion gene was done using interphase FISH technique and was confirmed molecularly using the RT-PCR technique.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17496935.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, Differentiation, B-Lymphocyte; 0 / RNA, Messenger; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


10. Huh J, Moon H, Chung W: A case of ABL deletion in a patient with precursor B cell lymphoblastic leukemia. Ann Hematol; 2008 Mar;87(3):239-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ABL deletion in a patient with precursor B cell lymphoblastic leukemia.
  • [MeSH-major] Chromosomes, Human, Pair 9 / genetics. Gene Deletion. Genes, abl / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Humans. In Situ Hybridization. Male

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846770.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down


11. Sachdeva MU, Ahluwalia J, Das R, Varma N, Garewal G: Role of FAB classification of acute leukemias in era of immunophenotyping. Indian J Pathol Microbiol; 2006 Oct;49(4):524-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Out of total of 469 cases of acute leukemias, 193 were diagnosed as Acute Lymphoblastic Leukemia (ALL), 200 as Acute Myeloid Leukemia (AML), and 76 cases diagnosed as Acute Leukemia, cytochemically undifferentiated.
  • [MeSH-major] Histocytochemistry / methods. Leukemia / classification. Leukemia, Myeloid / classification. Leukemia, Myeloid / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / classification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Acute Disease. Adult. Child. Child, Preschool. Cytogenetics / methods. Humans. Immunophenotyping / methods

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17183842.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] India
  •  go-up   go-down


12. Djordjević V, Dencić-Fekete M, Jovanović J, Drakulić D, Stevanović M, Janković G, Gotić M: Pattern of trisomy 1q in hematological malignancies: a single institution experience. Cancer Genet Cytogenet; 2008 Oct;186(1):12-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a pattern of partial trisomies and unbalanced whole-arm translocations of 1q in 10 patients: 5 with myelodysplastic syndrome, 3 with acute myeloid leukemia, and a single patient with acute lymphoblastic leukemia and myeloproliferative syndrome.
  • [MeSH-minor] Adult. Aged. Chromosome Painting. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Leukemia, Myeloid, Acute / genetics. Male. Middle Aged. Myelodysplastic Syndromes / genetics. Myeloproliferative Disorders / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18786437.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD: Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol; 2010 Oct;11(10):950-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
  • Dexrazoxane reduces cardiac damage during treatment with doxorubicin in children with acute lymphoblastic leukaemia (ALL).

  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Heart. 2008 Apr;94(4):525-33 [18347383.001]
  • [Cites] Cochrane Database Syst Rev. 2008;(2):CD003917 [18425895.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3777-84 [18669466.001]
  • [Cites] Am J Cardiol. 2008 Sep 15;102(6):761-6 [18774003.001]
  • [Cites] Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1311-7 [19018683.001]
  • [Cites] Cancer. 2009 Jan 1;115(1):23-35 [19072983.001]
  • [Cites] J Clin Oncol. 2009 May 10;27(14):2328-38 [19332714.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Jul;64(2):243-51 [19020877.001]
  • [Cites] Cardiovasc Toxicol. 2009 Jun;9(2):64-9 [19484391.001]
  • [Cites] N Engl J Med. 2009 Jun 25;360(26):2730-41 [19553647.001]
  • [Cites] J Am Coll Cardiol. 2009 Aug 4;54(6):491-8 [19643307.001]
  • [Cites] Br J Cancer. 2009 Sep 1;101(5):792-802 [19623174.001]
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1249-59 [19776406.001]
  • [Cites] Eur J Cancer. 2009 Nov;45(17):3027-34 [19744853.001]
  • [Cites] BMJ. 2009;339:b4606 [19996459.001]
  • [Cites] Curr Opin Pediatr. 2009 Oct;21(5):585-93 [19584723.001]
  • [Cites] Leukemia. 2010 Feb;24(2):371-82 [20010620.001]
  • [Cites] Leukemia. 2010 Feb;24(2):406-18 [20010621.001]
  • [Cites] Leukemia. 2010 Feb;24(2):265-84 [20010625.001]
  • [Cites] Leukemia. 2010 Feb;24(2):309-19 [20016528.001]
  • [Cites] Leukemia. 2010 Feb;24(2):285-97 [20016531.001]
  • [Cites] Leukemia. 2010 Feb;24(2):255-64 [20016536.001]
  • [Cites] Leukemia. 2010 Feb;24(2):335-44 [20016539.001]
  • [Cites] J Clin Oncol. 2010 Mar 10;28(8):1276-81 [20142585.001]
  • [Cites] J Clin Oncol. 2010 Mar 10;28(8):1308-15 [20142603.001]
  • [Cites] Toxicology. 2010 Apr 11;270(2-3):92-8 [20132857.001]
  • [Cites] J Am Soc Echocardiogr. 2010 May;23(5):465-95; quiz 576-7 [20451803.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 Jul;66(2):303-14 [19915844.001]
  • [Cites] JAMA. 2010 Jul 14;304(2):172-9 [20628130.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):2013-22 [20647396.001]
  • [Cites] J Korean Med Sci. 2010 Sep;25(9):1336-42 [20808678.001]
  • [Cites] Physiol Res. 2010;59(5):831-6 [20406046.001]
  • [Cites] J Am Coll Cardiol. 2011 Jan 4;57(1):76-85 [21185505.001]
  • [Cites] JAMA. 2007 Jun 27;297(24):2705-15 [17595271.001]
  • [Cites] Br J Pharmacol. 2007 Jul;151(6):771-8 [17519947.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3179; author reply 3180 [17634500.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4477-89 [17906209.001]
  • [Cites] Pathol Oncol Res. 2007;13(3):249-53 [17922055.001]
  • [Cites] J Pharmacol Exp Ther. 1995 Nov;275(2):1011-8 [7473127.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):328-31 [8636739.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1544-52 [9193351.001]
  • [Cites] Circulation. 1997 Oct 21;96(8):2641-8 [9355905.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):545-50 [9469339.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):818-24 [10071272.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2629-36 [15837978.001]
  • [Cites] Pediatrics. 2005 Jun;115(6):1613-22 [15930224.001]
  • [Cites] J Appl Physiol (1985). 2005 Aug;99(2):445-57 [15557009.001]
  • [Cites] Am Heart J. 2005 Sep;150(3):439-47 [16169321.001]
  • [Cites] Pediatr Blood Cancer. 2005 Dec;45(7):872-3 [16206201.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):561-78 [16351632.001]
  • [Cites] Ann Oncol. 2006 Apr;17(4):614-22 [16423847.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Blood. 2007 Feb 1;109(3):896-904 [17003366.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):493-500 [17290056.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Mar;133(3):668-75 [17320563.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2237-43 [10561281.001]
  • [Cites] J Am Coll Cardiol. 2000 Mar 1;35(3):569-82 [10716457.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • [Cites] Circulation. 2000 Sep 26;102(13):1542-8 [11182983.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3173-81 [11432883.001]
  • [Cites] Circulation. 2001 Jul 17;104(3):310-6 [11457750.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Oct;48(4):297-304 [11710630.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1677-82 [11896119.001]
  • [Cites] Biometrics. 2002 Sep;58(3):621-30 [12229997.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4517-22 [12454107.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1074-81 [12637473.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] Circulation. 2004 Jun 8;109(22):2749-54 [15148277.001]
  • [Cites] N Engl J Med. 2004 Jul 8;351(2):145-53 [15247354.001]
  • [Cites] Pharmacology. 1983;26(4):210-20 [6844396.001]
  • [Cites] Circulation. 1990 Apr;81(4):1161-72 [2138525.001]
  • [Cites] N Engl J Med. 1991 Mar 21;324(12):808-15 [1997853.001]
  • [Cites] J Am Coll Cardiol. 1992 Mar 1;19(3):619-29 [1538019.001]
  • [Cites] J Clin Oncol. 1992 May;10(5):810-7 [1569453.001]
  • [Cites] Med Pediatr Oncol. 1993;21(7):477-9 [8341214.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):740-7 [8151317.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1738-43 [7760889.001]
  • [Cites] Expert Opin Pharmacother. 2007 Jun;8(8):1039-58 [17516870.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4689-90; author reply 4690-1 [17925567.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4707-13 [17947717.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1106-11 [18309945.001]
  • (PMID = 20850381.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00165087
  • [Grant] United States / NICHD NIH HHS / HD / U01 HD052104; United States / NHLBI NIH HHS / HL / HL078522; United States / NHLBI NIH HHS / HL / HL095127; United States / NHLBI NIH HHS / HL / R01 HL087000; United States / NHLBI NIH HHS / HL / HL094100; United States / NHLBI NIH HHS / HL / F31 HL094100; United States / NICHD NIH HHS / HD / HD052102; United States / NHLBI NIH HHS / HL / HL053392; United States / NHLBI NIH HHS / HL / HL087000; United States / NCI NIH HHS / CA / R01 CA127642; United States / NHLBI NIH HHS / HL / HL079233; United States / NHLBI NIH HHS / HL / HL007188; United States / NHLBI NIH HHS / HL / HL087708; United States / NCI NIH HHS / CA / CA068484; United States / NHLBI NIH HHS / HL / R01 HL095127; United States / NHLBI NIH HHS / HL / R01 HL078522; United States / NIAID NIH HHS / AI / AI50274; United States / NICHD NIH HHS / HD / U01 HD052102; United States / NHLBI NIH HHS / HL / R13 HL087708; United States / NHLBI NIH HHS / HL / K30 HL004537; United States / NHLBI NIH HHS / HL / T32 HL007188; United States / NICHD NIH HHS / HD / HD80002; United States / NIAID NIH HHS / AI / U01 AI050274; United States / NICHD NIH HHS / HD / HD052104; United States / NCI NIH HHS / CA / CA127642; United States / NCI NIH HHS / CA / P01 CA068484; United States / NHLBI NIH HHS / HL / HL072705; United States / NHLBI NIH HHS / HL / R01 HL053392; United States / NHLBI NIH HHS / HL / HL004537; United States / NHLBI NIH HHS / HL / R01 HL072705
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Biomarkers; 0 / Cardiovascular Agents; 0 / Troponin T; 5AR83PR647 / Razoxane; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ NIHMS483981; NLM/ PMC3756093
  •  go-up   go-down


14. Devidas M, London WB, Anderson JR: The use of central laboratories and remote electronic data capture to risk-adjust therapy for pediatric acute lymphoblastic leukemia and neuroblastoma. Semin Oncol; 2010 Feb;37(1):53-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of central laboratories and remote electronic data capture to risk-adjust therapy for pediatric acute lymphoblastic leukemia and neuroblastoma.
  • COG has complex risk classification systems that are used to deliver risk-stratified therapy for many pediatric cancers, including clinical trials for acute lymphoblastic leukemia (ALL) and neuroblastoma (NB).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • (PMID = 20172365.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] ENG
  • [Grant] None / None / / U10 CA029139-22; United States / NCI NIH HHS / CA / U10 CA098413; None / None / / U10 CA098413-05; United States / NCI NIH HHS / CA / U10 CA098413-05; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098543-01; United States / NCI NIH HHS / CA / U10 CA029139-22
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS183364; NLM/ PMC2843557
  •  go-up   go-down


15. Mills KI, Gilkes AF: Clinical implications of gene expression profiling of acute myeloid leukemia. Curr Hematol Malig Rep; 2006 Jun;1(2):114-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Child. Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Leukemic. Humans. Mutation. Neoplasm Proteins / genetics. Patient Selection. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Prognosis. Translocation, Genetic. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2005 Mar;19(3):402-9 [15674361.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jun;43(2):113-27 [15751046.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3679-87 [15226186.001]
  • [Cites] Mol Cancer Ther. 2002 Oct;1(12):1035-42 [12481426.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1124-9 [11158605.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3618-20 [16046528.001]
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1189-98 [15878973.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1752-9 [11535508.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9381-91 [15543237.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Jun;37(2):149-58 [12696063.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3768-76 [16105978.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2646-54 [15251987.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Aug;37(4):396-405 [12800151.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1849-56 [12738660.001]
  • [Cites] Br J Haematol. 2005 Jul;130(2):203-8 [16029448.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Oncogene. 2005 Feb 24;24(9):1580-8 [15674343.001]
  • [Cites] Genes Chromosomes Cancer. 2003 May;37(1):72-8 [12661007.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2113-9 [15951308.001]
  • [Cites] Eur J Haematol. 2005 Sep;75(3):185-92 [16104873.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Mar;42(3):299-307 [15609343.001]
  • [Cites] Blood. 2005 Aug 1;106(3):899-902 [15831697.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Jul;37(3):237-51 [12759922.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3733-9 [16076867.001]
  • [Cites] Int J Oncol. 2003 Sep;23 (3):617-25 [12888896.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):624-33 [14726504.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1419-22 [15870172.001]
  • [Cites] Leuk Res. 2003 Feb;27(2):125-31 [12526918.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Haematologica. 2003 Jan;88(1):19-24 [12551822.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10008-13 [12105272.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1605-16 [15084693.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • (PMID = 20425341.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 39
  •  go-up   go-down


16. Mizgirev IV, Revskoy S: A new zebrafish model for experimental leukemia therapy. Cancer Biol Ther; 2010 Jun 1;9(11):895-902
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A transplantable T-cell acute lymphoblastic leukemia (T-ALL) line ZL1 was induced by mosaic expression of zRag2-EGFP-mMyc transgene and underwent more than 20 consecutive transplantations in adult syngeneic fish prior to the experiments.
  • [MeSH-minor] Animals. Animals, Genetically Modified. Cell Line, Tumor. Cyclophosphamide / pharmacology. Dose-Response Relationship, Drug. Green Fluorescent Proteins / genetics. Green Fluorescent Proteins / metabolism. Humans. Larva / drug effects. Larva / genetics. Larva / metabolism. Microscopy, Fluorescence. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Prednisolone / pharmacology. Survival Analysis. Time Factors. Vincristine / pharmacology

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • ZFIN. ZFIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20339318.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 139311
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 147336-22-9 / Green Fluorescent Proteins; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


17. Ando T, Yujiri T, Nomiyama J, Mitani N, Seguchi M, Matsubara A, Tanizawa Y: Allogeneic peripheral blood stem cell transplantation from related donors mismatched at 2 HLA loci in the host-versus-graft direction. Tohoku J Exp Med; 2008 Feb;214(2):159-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report 2 patients (1 with acute myeloblastic leukemia and another with lymphoblastic lymphoma) who were transplanted with peripheral blood stem cells (PBSCs) obtained from related donors mismatched at 2 HLA loci in the HVG direction but completely matched in the GVH direction.
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18285674.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


18. Abutalib SA, Wetzler M, Stock W: Looking toward the future: novel strategies based on molecular pathogenesis of acute lymphoblastic leukemia. Hematol Oncol Clin North Am; 2009 Oct;23(5):1099-119, vii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Looking toward the future: novel strategies based on molecular pathogenesis of acute lymphoblastic leukemia.
  • There has been exponential growth in our understanding of the pathobiology of acute lymphoblastic leukemia (ALL) leading to the discovery of new prognostic markers and potential new treatment strategies.
  • [MeSH-major] Pathology, Molecular / trends. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Humans. Prognosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19825455.001).
  • [ISSN] 1558-1977
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 136
  •  go-up   go-down


19. Leslie M, Case MC, Hall AG, Coulthard SA: Expression levels of asparagine synthetase in blasts from children and adults with acute lymphoblastic leukaemia. Br J Haematol; 2006 Mar;132(6):740-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression levels of asparagine synthetase in blasts from children and adults with acute lymphoblastic leukaemia.
  • L-asparaginase is active in the treatment of acute lymphoblastic leukaemia (ALL) through the depletion of serum asparagine.
  • NPBMC versus child ALL (Tukeys multiple comparison test, P < 0.05); child ALL versus child AML (P < 0.001) and adult ALL versus adult AML (P < 0.01) were all significant and support the hypothesis that selectivity to treatment with l-asparaginase is due, at least in part, to lower AS expression.
  • [MeSH-major] Aspartate-Ammonia Ligase / analysis. Lymphocytes / enzymology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Cell Line, Tumor. Child. Child, Preschool. Female. Humans. Infant. Leukemia, Myeloid / enzymology. Leukocytes, Mononuclear / enzymology. Male. Middle Aged. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction / methods

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16487174.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 6.3.1.1 / Aspartate-Ammonia Ligase
  •  go-up   go-down


20. Nelson BP, Treaba D, Goolsby C, Williams S, Dewald G, Gordon L, Peterson LC: Surface immunoglobulin positive lymphoblastic leukemia in adults; a genetic spectrum. Leuk Lymphoma; 2006 Jul;47(7):1352-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surface immunoglobulin positive lymphoblastic leukemia in adults; a genetic spectrum.
  • Precursor B-lymphoblastic leukemia is typically surface immunoglobulin (sIg) negative.
  • Although rare cases of sIg+ precursor lymphoblastic leukemia are recognized, sIg+ leukemia often represent leukemic phase of Burkitt lymphoma or other non-Hodgkin lymphoma such as blastic mantle cell lymphoma.
  • This study reports four adults, two women (56 and 58 years old) and two men (35 and 41 years old) with lymphoblastic leukemia that displayed lambda, surface immunoglobulin restriction (sIg+).
  • Genetic abnormalities were detected in all cases and in three cases included abnormalities commonly present in precursor lymphoblastic leukemia.
  • These cases illustrate that lymphoblastic leukemias occurring in adults exhibit a morphologic, immunophenotypic as well as a genetic spectrum and represent either non-Hodgkin lymphoma or precursor lymphoblastic leukemia.
  • [MeSH-major] Immunoglobulins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Translocation, Genetic
  • [MeSH-minor] Adult. Biopsy. Bone Marrow / metabolism. Burkitt Lymphoma / metabolism. Female. Gene Deletion. Humans. Immunohistochemistry. Immunophenotyping / methods. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923568.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulins
  •  go-up   go-down


21. Ozgen IT, Dagdemir A, Elli M, Saraymen R, Pinarli FG, Fisgin T, Albayrak D, Acar S: Hair selenium status in children with leukemia and lymphoma. J Pediatr Hematol Oncol; 2007 Aug;29(8):519-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hair selenium status in children with leukemia and lymphoma.
  • Low serum Se levels have been reported in pediatric and adult patients with cancers.
  • On the other hand, hair Se levels, predicting the long-term body Se status, have been reported in only adult patients with cancer.
  • Thirty patients with leukemia (n=17) and lymphoma (n=13), and 25 healthy controls were enrolled to the study.
  • Children with lymphoma had lower Se than the children with acute lymphoblastic leukemia but not statistically significant [547.03+/-283.67 ng/g vs. 758.67+/-361.05 ng/g (P>0.05)].
  • In this study, we found that hair Se levels of the children with leukemia and lymphoma, especially those of malnourished patients, were lower than those of controls.
  • [MeSH-major] Child Nutrition Disorders / complications. Hodgkin Disease / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Selenium / deficiency

  • MedlinePlus Health Information. consumer health - Child Nutrition.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762491.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] H6241UJ22B / Selenium
  •  go-up   go-down


22. Goto N, Hara T, Tsurumi H, Ogawa K, Kitagawa J, Kanemura N, Kasahara S, Yamada T, Shimizu M, Nakamura M, Matsuura K, Moriwaki H: Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies. Am J Hematol; 2010 Nov;85(11):872-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Underlying diseases comprised acute lymphoblastic leukemia (n = 4), acute myeloid leukemia (n = 20), multiple myeloma (n = 3), and non-Hodgkin's lymphoma (n = 26).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antifungal Agents. Antineoplastic Agents / adverse effects. Drug Monitoring. Drug-Related Side Effects and Adverse Reactions. Female. Fever / drug therapy. Fever / microbiology. Humans. Kidney Diseases. Liver Diseases. Male. Middle Aged. Mycoses / chemically induced. Mycoses / drug therapy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc.
  • (PMID = 20882524.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Antineoplastic Agents; 0 / Echinocandins; 0 / Lipopeptides; R10H71BSWG / micafungin
  •  go-up   go-down


23. Fukuda H, Mukai H: Cutaneous endometriosis in the umbilical region: the usefulness of CD10 in identifying the interstitium of ectopic endometriosis. J Dermatol; 2010 Jun;37(6):545-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD10 was initially described as a tumor-specific antigen found in acute lymphoblastic leukemia.
  • Recently, the usefulness of CD10 in diagnosing endometriosis in addition to various types of lymphoma or blood cancer has been confirmed, and in our case it also proved to be as useful as estrogen receptor or progesterone receptor in the definitive diagnosis of endometriosis.
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20536670.001).
  • [ISSN] 1346-8138
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


24. DeAngelo DJ: Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Hematol Oncol Clin North Am; 2009 Oct;23(5):1121-35, vii-viii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
  • Nelarabine has significant activity in patients with T-cell acute lymphoblastic leukemia (T-ALL) and lymphoma (T-LBL).
  • [MeSH-major] Arabinonucleosides / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Drug Resistance, Neoplasm. Humans. Salvage Therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19825456.001).
  • [ISSN] 1558-1977
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arabinonucleosides; 60158CV180 / nelarabine
  • [Number-of-references] 34
  •  go-up   go-down


25. Counsel P, Khangure M: Myelopathy due to intrathecal chemotherapy: magnetic resonance imaging findings. Clin Radiol; 2007 Feb;62(2):172-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Female. Humans. Injections, Spinal. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Spinal Cord / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Spinal Cord Diseases.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207701.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


26. Buyukavci M, Olgun H, Ceviz N: The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol; 2005 Apr;28(2):201-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the cardiac safety of granisetron and ondansetron has been investigated in several adult studies, there is no report investigating the effects of those agents on electrocardiography (ECG) in children.
  • The effects of intravenously infused (over 30 seconds) 0.1 mg/kg ondansetron and 40 microg/kg granisetron on ECG were assessed in 22 children receiving high-dose methotrexate therapy for acute lymphoblastic leukemia.
  • [MeSH-major] Antiemetics / pharmacology. Granisetron / pharmacology. Heart Rate / drug effects. Ondansetron / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Serotonin Antagonists / pharmacology

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Clin Oncol. 2005 Dec;28(6):634-5 [16317278.001]
  • (PMID = 15803017.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiemetics; 0 / Antimetabolites, Antineoplastic; 0 / Serotonin Antagonists; 4AF302ESOS / Ondansetron; WZG3J2MCOL / Granisetron; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


27. Brisco MJ, Latham S, Sutton R, Hughes E, Wilczek V, van Zanten K, Budgen B, Bahar AY, Malec M, Sykes PJ, Kuss BJ, Waters K, Venn NC, Giles JE, Haber M, Norris MD, Marshall GM, Morley AA: Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia. J Mol Diagn; 2009 May;11(3):194-200
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia.
  • Molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia were identified by determining, at the time of diagnosis, the repertoire of rearrangements of the immunoglobulin heavy chain (IGH) gene using segment-specific variable (V), diversity (D), and junctional (J) primers in two different studies that involved a total study population of 75 children and 18 adults.
  • IGH repertoire analysis at diagnosis has potential advantages for the identification of molecular markers for the quantification of minimal residual disease in acute lymphoblastic leukemia cases.
  • [MeSH-major] Cell Lineage. Gene Rearrangement, B-Lymphocyte. Immunoglobulin Heavy Chains / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Child. Cooperative Behavior. DNA, Neoplasm / genetics. Genetic Markers. Genome, Human / genetics. Humans. Neoplasm, Residual / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Aug;14(8):1426-35 [10942239.001]
  • [Cites] J Mol Diagn. 2009 May;11(3):201-10 [19324989.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2315-23 [11895762.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Mar;15(1):71-90 [11987917.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4520-6 [12946997.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Leukemia. 2004 May;18(5):934-8 [15029212.001]
  • [Cites] Blood. 2004 May 15;103(10):3798-804 [14656882.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W435-40 [15215425.001]
  • [Cites] Blood. 1987 Oct;70(4):1079-83 [3477297.001]
  • [Cites] Leukemia. 1990 Nov;4(11):727-31 [2172664.001]
  • [Cites] Blood. 1993 Jul 15;82(2):581-9 [8329713.001]
  • [Cites] Lancet. 1994 Jan 22;343(8891):196-200 [7904666.001]
  • [Cites] Leukemia. 1995 Nov;9(11):1847-50 [7475273.001]
  • [Cites] Leukemia. 1997 Dec;11(12):2192-9 [9447840.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):591-8 [9718378.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] Leukemia. 1999 Jan;13(1):110-8 [10049045.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D593-7 [15608269.001]
  • [Cites] Leukemia. 2007 Apr;21(4):604-11 [17287850.001]
  • [Cites] Leukemia. 2007 Apr;21(4):706-13 [17287857.001]
  • [Cites] Blood. 2007 Jul 15;110(2):632-9 [17371950.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1607-11 [17485550.001]
  • [Cites] Leukemia. 2008 Apr;22(4):771-82 [18239620.001]
  • [Cites] Leukemia. 2001 Jan;15(1):134-40 [11243381.001]
  • (PMID = 19324994.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers; 0 / Immunoglobulin Heavy Chains
  • [Other-IDs] NLM/ PMC2671336
  •  go-up   go-down


28. Yu B, Du JR, Xie JL, Yu R, Zheng XD, Zhu H, Zhou XG: [Clinicopathologic study of 128 cases of T-lymphoblastic lymphoma/leukemia]. Zhonghua Bing Li Xue Za Zhi; 2010 Jul;39(7):452-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of 128 cases of T-lymphoblastic lymphoma/leukemia].
  • OBJECTIVE: To clarify clinical and morphological features and immunophenotype of T lymphoblastic lymphoma/leukaemia (T-LBL/ALL) and to further improve the knowledge and diagnostic accuracy for T-ALL/LBL.
  • [MeSH-major] Antigens, CD3 / metabolism. Gene Rearrangement, T-Lymphocyte. Neprilysin / metabolism. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD34 / metabolism. Antigens, CD7 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. B-Cell-Specific Activator Protein / metabolism. Child. Child, Preschool. DNA Nucleotidylexotransferase / metabolism. Female. Follow-Up Studies. Humans. Ki-67 Antigen / metabolism. Lymphatic Metastasis. Male. Middle Aged. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21055173.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD34; 0 / Antigens, CD7; 0 / B-Cell-Specific Activator Protein; 0 / Ki-67 Antigen; 0 / PAX5 protein, human; EC 2.7.7.31 / DNA Nucleotidylexotransferase; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


29. Specchia G, Pastore D, Carluccio P, Liso A, Mestice A, Rizzi R, Ciuffreda L, Pietrantuono G, Liso V: FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Ann Hematol; 2005 Nov;84(12):792-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
  • Relapsed or refractory adult acute lymphoblastic leukemias (ALL) have poor prognosis.
  • Twenty three patients with relapsed/refractory adult ALL were treated with fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Disease-Free Survival. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / adverse effects. Humans. Idarubicin / administration & dosage. Idarubicin / adverse effects. Leukocyte Count. Liver / injuries. Male. Middle Aged. Mucositis / etiology. Platelet Count. Recurrence. Remission Induction. Retrospective Studies. Salvage Therapy. Transplantation, Homologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / adverse effects. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16047203.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


30. Karp JE, Ricklis RM, Balakrishnan K, Briel J, Greer J, Gore SD, Smith BD, McDevitt MA, Carraway H, Levis MJ, Gandhi V: A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood; 2007 Sep 15;110(6):1762-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At dose level 1 (20 mg/m(2) clofarabine + cyclophosphamide, 6 patients) and dose level 0 (10 mg/m(2) clofarabine + cyclophosphamide, 12 patients) overall response rates were 50% and 30%, respectively, with responses in 4 (67%) of 6 patients with refractory acute lymphoblastic leukemia.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Feb 1;105(3):940-7 [15486072.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Apr;55(4):361-8 [15723262.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4079-88 [15767648.001]
  • [Cites] Blood. 2006 Feb 1;107(3):885-91 [16219797.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1917-23 [16622268.001]
  • [Cites] Blood. 2006 Jul 1;108(1):45-51 [16403905.001]
  • [Cites] Blood. 2006 Jul 15;108(2):473-9 [16551966.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2392-8 [16778146.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4187-93 [16954499.001]
  • [Cites] Blood. 2007 Jan 15;109(2):405-11 [17008537.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3537-43 [11071652.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1414-20 [11230486.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3580-9 [11705880.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1167-73 [12637486.001]
  • [Cites] Leuk Lymphoma. 2003 May;44(5):859-66 [12802926.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4347-50 [12907603.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2379-86 [12791647.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6335-42 [14695132.001]
  • [Cites] Blood. 2004 Feb 1;103(3):784-9 [14551141.001]
  • [Cites] Leukemia. 2004 Feb;18(2):293-302 [14671635.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):331-5 [14751500.001]
  • [Cites] Cancer Res. 1986 Aug;46(8):4205-7 [3731087.001]
  • [Cites] Anal Biochem. 1989 Aug 1;180(2):222-6 [2554751.001]
  • [Cites] J Natl Cancer Inst. 1991 Apr 17;83(8):557-64 [2005641.001]
  • [Cites] Cancer Res. 1991 May 1;51(9):2386-94 [1707752.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2970-4 [1348362.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2847-52 [7540950.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4979-89 [8652810.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3030-7 [8674058.001]
  • [Cites] J Biol Chem. 1998 Mar 6;273(10):5858-68 [9488723.001]
  • (PMID = 17562873.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00293410
  • [Grant] United States / NCI NIH HHS / CA / R01 CA057629; United States / NCI NIH HHS / CA / CA57629
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 0 / H2AFX protein, human; 0 / Histones; 762RDY0Y2H / clofarabine; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ PMC1976362
  •  go-up   go-down


31. Ram R, Gafter-Gvili A, Vidal L, Paul M, Ben-Bassat I, Shpilberg O, Raanani P: Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis. Cancer; 2010 Jul 15;116(14):3447-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis.
  • BACKGROUND: The optimal postremission therapy in adults with acute lymphoblastic leukemia (ALL) is still a matter of debate.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Randomized Controlled Trials as Topic. Recurrence. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Cancer Society.
  • (PMID = 20564092.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


32. Ranade A, Selegean S, Sandhu G, Ghali V, Shah VP: Acute lymphoblastic leukemia in a patient with type 1 Gaucher disease developing 1 year after discontinuation of enzyme replacement therapy. Am J Hematol; 2010 Nov;85(11):908-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia in a patient with type 1 Gaucher disease developing 1 year after discontinuation of enzyme replacement therapy.
  • [MeSH-major] Enzyme Replacement Therapy. Gaucher Disease / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology
  • [MeSH-minor] Adult. Blood Buffy Coat / pathology. Humans. Male


33. Specchia G, Buquicchio C, Pansini N, Di Serio F, Liso V, Pastore D, Greco G, Ciuffreda L, Mestice A, Liso A: Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J Lab Clin Med; 2005 Apr;145(4):212-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Anthracyclines / adverse effects. Antibiotics, Antineoplastic / adverse effects. Heart Diseases / blood. Heart Diseases / chemically induced. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Troponin I / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers / blood. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962840.001).
  • [ISSN] 0022-2143
  • [Journal-full-title] The Journal of laboratory and clinical medicine
  • [ISO-abbreviation] J. Lab. Clin. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic; 0 / Biomarkers; 0 / Troponin I
  •  go-up   go-down


34. Pane F, Cimino G, Izzo B, Camera A, Vitale A, Quintarelli C, Picardi M, Specchia G, Mancini M, Cuneo A, Mecucci C, Martinelli G, Saglio G, Rotoli B, Mandelli F, Salvatore F, Foà R, GIMEMA group: Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia; 2005 Apr;19(4):628-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.
  • Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has a dismal prognosis.
  • Our data indicate that, as already shown in children, adult Ph+ ALL patients have a heterogeneous sensitivity to treatment, and that early quantification of residual disease is a prognostic parameter in this disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fusion Proteins, bcr-abl / genetics. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Asparaginase / therapeutic use. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm, Residual / drug therapy. Neoplasm, Residual / genetics. Neoplasm, Residual / mortality. Predictive Value of Tests. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744351.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


35. Hirokawa M, Sato H, Kawabata Y, Sawada K: Vaginal outflow tract obstruction associated with chronic Graft-versus-host disease following allogeneic peripheral blood stem cell transplantation. Int J Hematol; 2006 Feb;83(2):181-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Chronic Disease. Female. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation, Homologous


36. Baheti AD, Mahore AS, Zade BP, Jalali R: Meningioma and cavernous angioma following childhood radiotherapy. J Cancer Res Ther; 2010 Jul-Sep;6(3):333-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prophylactic cranial irradiation has been a part of multimodality management of acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Hemangioma / etiology. Meningioma / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Humans. Male


37. Mitsui H, Nakazawa T, Tanimura A, Karasuno T, Hiraoka A: Donor cell-derived chronic myeloproliferative disease with t(7;11)(p15;p15) after cord blood transplantation in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol; 2007 Aug;86(2):192-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donor cell-derived chronic myeloproliferative disease with t(7;11)(p15;p15) after cord blood transplantation in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
  • A 41-year-old man developed precursor B-cell acute lymphoblastic leukemia with a karyotype of 46, XY, t(9;22)(q34;q11) and inv(9)(p11;q13), for which he received CBT from a sex-mismatched donor at the first complete remission of the leukemia.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / adverse effects. Myeloproliferative Disorders / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Translocation, Genetic
  • [MeSH-minor] Adult. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 7. Chronic Disease. Humans. Infant. Male. Tissue Donors


38. Maniar TN, Braunstein I, Keefe S, Hussen S, Abrams T, De Michele A, El-Deiry WS: Childhood ALL and second neoplasms. Cancer Biol Ther; 2007 Oct;6(10):1525-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Second malignancies are a significant concern for survivors of childhood acute lymphoblastic leukemia (ALL), in particular patients who have been treated with cranial irradiation.
  • [MeSH-major] Breast Neoplasms / epidemiology. Meningeal Neoplasms / epidemiology. Meningioma / epidemiology. Neoplasms, Second Primary / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Male. Risk

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952026.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 96
  •  go-up   go-down


39. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Chen YH, Zhang XH, Lu DP: Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant; 2009 Feb;15(2):257-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 3-year probability of LFS for acute myelogenous leukemia (AML) was 70.7% and 55.9%, and for acute lymphoblastic leukemia (ALL) it was 59.7% and 24.8% in standard-risk and high-risk groups, respectively.
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Graft vs Host Disease / immunology. HLA-A Antigens. HLA-B Antigens. HLA-DR Antigens. Humans. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation, Homologous / immunology. Treatment Outcome. Young Adult


40. Yamanoha A, Nagasaki A, Nakachi S, Kinjo S, Takasu N: Air-leak syndrome associated with bronchiolitis obliterans after allogeneic peripheral blood stem cell transplantation. Int J Hematol; 2007 Feb;85(2):95-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Bronchiolitis Obliterans / etiology. Graft vs Host Disease / etiology. Mediastinal Emphysema / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Acute Disease. Adult. Anti-Inflammatory Agents / administration & dosage. Cyclosporine / administration & dosage. Cytomegalovirus Infections / drug therapy. Cytomegalovirus Infections / etiology. Humans. Immunosuppressive Agents / administration & dosage. Male. Peripheral Blood Stem Cell Transplantation. Prednisone / administration & dosage. Syndrome

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Bronchiolitis Obliterans.
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17321983.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; VB0R961HZT / Prednisone
  •  go-up   go-down


41. Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P, Larson RA, Parsons S, Seidenfeld J, Weisdorf D, McCarthy PL Jr: The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant; 2006 Jan;12(1):1-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review.
  • Evidence supporting the role of hematopoietic stem cell transplantation (SCT) in the therapy of acute lymphoblastic leukemia in adults (> or =15 years) is presented and critically evaluated in this systematic evidence-based review.
  • Treatment recommendations based on the evidence are presented and were reached unanimously by a panel of acute lymphoblastic leukemia experts.
  • The priority areas of needed future research for adult acute lymphoblastic leukemia are: definition of patients at high risk in first complete remission, beyond Philadelphia chromosome positive; outcomes of SCT in older (>50 years) adults; determination if reduced intensity versus myeloablative conditioning regimens yield an equivalent graft-versus-leukemia effect with reduced toxicity; monitoring of minimal residual disease to achieve disease control before SCT; and the use of cord blood and other alternative sources of stem cells for use in adult SCT recipients.
  • [MeSH-major] Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16399566.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 83
  •  go-up   go-down


42. Fan LP, Shen JZ, Ye BG, Lin FA, Fu HY, Zhou HR, Shen SF, Yu AF: [Detection of p16 gene methylation status in adult patients with acute leukemia by using n-MSP]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr;15(2):258-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of p16 gene methylation status in adult patients with acute leukemia by using n-MSP].
  • The study was aimed to explore the relationship between patterns of methylation or deletion and the development of acute leukemia, and further to clarify the possible mechanism in the development of adult acute leukemia.
  • Nested methylation-specific polymerase chain reaction (n-MSP) was adopted to analyze p16 gene methylation or deletion patterns in 82 adult acute leukemia patients with different subtypes and stages.
  • The results indicated that rate of p16 gene methylation was 39.0% in 82 adult acute leukemia patients, among them, 41.4% in acute myelogenous leukemia (AML) and 33.3% in acute lymphoblastic leukemia (ALL).
  • It is concluded that methylation of p16 gene may play a more important role than homozygous deletion of p16 gene in the leukemogenesis and progression of adult acute leukemia.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493327.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


43. Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A, O'Neil J, Gutierrez A, Ivanova E, Perna I, Lin E, Mani V, Jiang S, McNamara K, Zaghlul S, Edkins S, Stevens C, Brennan C, Martin ES, Wiedemeyer R, Kabbarah O, Nogueira C, Histen G, Aster J, Mansour M, Duke V, Foroni L, Fielding AK, Goldstone AH, Rowe JM, Wang YA, Look AT, Stratton MR, Chin L, Futreal PA, DePinho RA: Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature; 2007 Jun 21;447(7147):966-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we engineered lymphoma-prone mice with chromosomal instability to assess the usefulness of mouse models in cancer gene discovery and the extent of cross-species overlap in cancer-associated copy number aberrations.
  • Along with targeted re-sequencing, our comparative oncogenomic studies identified FBXW7 and PTEN to be commonly deleted both in murine lymphomas and in human T-cell acute lymphoblastic leukaemia/lymphoma (T-ALL).
  • [MeSH-major] Chromosomal Instability / genetics. Chromosome Aberrations. Conserved Sequence / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, T-Cell / genetics

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Aug 10;406(6796):641-5 [10949306.001]
  • [Cites] Cell Cycle. 2005 Oct;4(10):1356-9 [16131838.001]
  • [Cites] Nat Genet. 2001 Jun;28(2):155-9 [11381263.001]
  • [Cites] Adv Cancer Res. 2001;83:209-54 [11665719.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):459-64 [11694878.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Cell. 2002 Jun 28;109(7):811-21 [12110179.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):149-55 [12204535.001]
  • [Cites] Cell. 2003 Jan 24;112(2):243-56 [12553912.001]
  • [Cites] Nature. 2003 Feb 6;421(6923):643-8 [12540856.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5352-6 [14500367.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8188-96 [14678974.001]
  • [Cites] Nat Immunol. 2004 Mar;5(3):247-53 [14985712.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):177-83 [14993899.001]
  • [Cites] Nature. 2004 Mar 4;428(6978):77-81 [14999283.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9067-72 [15199222.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4394-9 [15231645.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2954-63 [15254063.001]
  • [Cites] Cancer Lett. 2004 Sep 15;213(1):11-20 [15312679.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Biostatistics. 2004 Oct;5(4):557-72 [15475419.001]
  • [Cites] Genes Dev. 1991 Feb;5(2):160-74 [1995414.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Cell. 1995 Oct 20;83(2):289-99 [7585946.001]
  • [Cites] Nature. 1998 May 28;393(6683):382-6 [9620803.001]
  • [Cites] Curr Biol. 1998 Oct 22;8(21):1169-78 [9799734.001]
  • [Cites] Cell. 1999 May 14;97(4):527-38 [10338216.001]
  • [Cites] Nature. 2004 Dec 9;432(7018):775-9 [15592418.001]
  • [Cites] Cell. 2004 Dec 17;119(6):847-60 [15607980.001]
  • [Cites] Cell. 2004 Dec 17;119(6):861-72 [15607981.001]
  • [Cites] Nat Genet. 2005 Jan;37(1):48-55 [15608639.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Nat Genet. 2005 Jun;37 Suppl:S11-7 [15920524.001]
  • [Cites] Gynecol Oncol. 2005 Jul;98(1):124-8 [15913747.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11361-6 [16357143.001]
  • [Cites] Blood. 2006 Jan 15;107(2):781-5 [16166587.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Apr;45(4):338-48 [16323170.001]
  • [Cites] Leukemia. 2006 Mar;20(3):537-9 [16424867.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5947-52 [16585505.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):313-25 [16616336.001]
  • [Cites] Cell. 2006 Jun 30;125(7):1253-67 [16814713.001]
  • [Cites] Cell. 2006 Jun 30;125(7):1269-81 [16814714.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19848-53 [17167050.001]
  • [Cites] Cell Cycle. 2007 Apr 15;6(8):927-30 [17404512.001]
  • [Cites] Nat Cell Biol. 2005 Jul;7(7):706-11 [15965466.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9625-30 [15983384.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7591-5 [16140923.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6597-604 [16007165.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1940-6 [10961898.001]
  • (PMID = 17515920.001).
  • [ISSN] 1476-4687
  • [Journal-full-title] Nature
  • [ISO-abbreviation] Nature
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE7615
  • [Grant] United Kingdom / Wellcome Trust / / 077012; United Kingdom / Wellcome Trust / / 088340; United Kingdom / Medical Research Council / / G0500389; United Kingdom / Wellcome Trust / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC2714968; NLM/ UKMS27310
  •  go-up   go-down


44. Pan JL, Xue YQ, Jiang HY, Zhu YJ, Ma L, Li TY, Wang Y, Wu YF: [Clinical and experimental study of 7 cases of acute lymphoblastic leukemia with dic(7;9) (pll;pll)]. Zhonghua Xue Ye Xue Za Zhi; 2005 Aug;26(8):485-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and experimental study of 7 cases of acute lymphoblastic leukemia with dic(7;9) (pll;pll)].
  • OBJECTIVE: To investigate the laboratory and clinical features of 7 cases of acute lymphoblastic leukemia (ALL) with dic(7;9) (pll;pll).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Chromosomes, Human, Pair 7 / genetics. Chromosomes, Human, Pair 9 / genetics. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16383241.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


45. Lutz C, Massenkeil G, Nagy M, Neuburger S, Tamm I, Rosen O, Dörken B, Arnold R: A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant; 2008 May;41(9):805-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation.
  • The outcome of patients with acute lymphoblastic leukemia (ALL) receiving therapeutic donor lymphocyte infusions (DLIs) in relapse after stem cell transplantation (SCT) is poor.
  • [MeSH-major] Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation. Living Donors. Lymphocyte Transfusion. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control. Transplantation Chimera
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Chronic Disease. Disease-Free Survival. Female. Follow-Up Studies. Graft vs Host Disease / mortality. Graft vs Host Disease / therapy. Humans. Male. Middle Aged. Recurrence. Remission Induction. Retrospective Studies. Survival Rate. Time Factors. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18195682.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


46. Wang GR, Xu Y, Zou DH, Zhao YZ, Wang M, Han MZ, Feng SZ, Yan WW, Qiu LG: [Autologous versus allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Aug;28(4):544-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autologous versus allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia].
  • OBJECTIVE: To explore the efficacy of autologous or allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia (ALL) and investigate its relevant prognostic factors.
  • METHODS: A total of 96 adult patients with ALL who had admitted to our hospital from November 1986 to June 2004 were followed up till February 28, 2005.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16995310.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


47. Appel IM, den Boer ML, Meijerink JP, Veerman AJ, Reniers NC, Pieters R: Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood; 2006 Jun 1;107(11):4244-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia.
  • L-asparaginase (L-Asp) is an effective drug for treatment of children with acute lymphoblastic leukemia (ALL).
  • No significant difference of AS mRNA up-regulation was found between precursor B- and T-ALL or between hyperdiploids, TEL/AML1 rearranged ALL or absence of genetic abnormalities.
  • [MeSH-major] Asparaginase / pharmacology. Aspartate-Ammonia Ligase / genetics. Polyethylene Glycols / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Up-Regulation / drug effects
  • [MeSH-minor] Adolescent. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Female. Humans. Infant. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / pathology. Male. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. RNA, Neoplasm / analysis. RNA, Neoplasm / drug effects. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497975.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Neoplasm; 0 / pegaspargase; 30IQX730WE / Polyethylene Glycols; EC 3.5.1.1 / Asparaginase; EC 6.3.1.1 / Aspartate-Ammonia Ligase
  •  go-up   go-down


48. Karam A, Eveillard JR, Ianoto JC, Quinio D, Le Flohic AM, Le Roy JP, Misery L, Berthou C: [Disseminated cutaneous and visceral fusariosis in an aplastic patient: an unusual digestive entry]. Ann Dermatol Venereol; 2005 Mar;132(3):255-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of cutaneous and systemic fusariosis due to Fusarium moniliforme in a patient with acute lymphoblastic leukemia.
  • [MeSH-major] Fusarium / pathogenicity. Mycoses / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Adult. Amsacrine / administration & dosage. Antifungal Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Diet. Humans. Immunocompromised Host. Male. Pyrimidines / therapeutic use. Triazoles / therapeutic use. Voriconazole

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. AMSACRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15924050.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; 00DPD30SOY / Amsacrine; 04079A1RDZ / Cytarabine; JFU09I87TR / Voriconazole
  •  go-up   go-down


49. Kim DH, Jung HD, Kwack DH, Lee NY, Sohn SK, Baek JH, Kim JG, Suh JS, Lee KB, Shin IH: Predicting outcomes of HLA-identical allogeneic stem cell transplants from variable number of tandem repeat disparity between donors and recipients. Haematologica; 2006 Jan;91(1):71-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patients were transplanted because of acute myeloid leukemia (ns=48), acute lymphoblastic leukemia (n=8), chronic myeloid leukemia (n=15), non-Hodgkin's lymphoma (n=18) and myelodysplastic syndrome (n=3).
  • [MeSH-minor] Adolescent. Adult. Female. Graft vs Host Disease / genetics. Hematologic Neoplasms / mortality. Hematologic Neoplasms / therapy. Humans. Male. Middle Aged. Prognosis. Survival Analysis. Transplantation, Homologous

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434373.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


50. dos Santos NR, Williame M, Gachet S, Cormier F, Janin A, Weih D, Weih F, Ghysdael J: RelB-dependent stromal cells promote T-cell leukemogenesis. PLoS One; 2008;3(7):e2555
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RelB deficiency delayed leukemia onset in the TEL-JAK2 transgenic mouse model of human T acute lymphoblastic leukemia.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / metabolism. Stromal Cells / metabolism. Transcription Factor RelB / metabolism

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2007 Jan;13(1):70-7 [17173050.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3777-85 [16896157.001]
  • [Cites] Haematologica. 2007 Feb;92(2):264-6 [17296584.001]
  • [Cites] Annu Rev Immunol. 2007;25:649-79 [17291187.001]
  • [Cites] Leukemia. 2000 Mar;14(3):399-402 [10720133.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3891-9 [10845925.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3337-48 [10880446.001]
  • [Cites] Eur J Immunol. 2000 Jul;30(7):1884-93 [10940877.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2410-4 [10946265.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):862-71 [11843820.001]
  • [Cites] Immunity. 2002 Oct;17(4):525-35 [12387745.001]
  • [Cites] EMBO J. 2003 Jan 2;22(1):121-30 [12505990.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12006-12 [12556537.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23278-84 [12709443.001]
  • [Cites] Immunol Rev. 2003 Oct;195:91-105 [12969313.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2593-6 [12816868.001]
  • [Cites] Haematologica. 2003 Nov;88(11):1229-37 [14607751.001]
  • [Cites] J Clin Invest. 2003 Nov;112(10):1495-505 [14617751.001]
  • [Cites] Genes Dev. 2004 Sep 15;18(18):2195-224 [15371334.001]
  • [Cites] EMBO J. 2004 Oct 27;23(21):4202-10 [15470505.001]
  • [Cites] Blood. 2007 May 1;109(9):3972-81 [17192390.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2700-7 [17119127.001]
  • [Cites] Blood. 2007 Jul 15;110(2):743-51 [17405906.001]
  • [Cites] Cancer Cell. 2007 Aug;12(2):115-30 [17692804.001]
  • [Cites] Cancer Cell. 2007 Aug;12(2):131-44 [17692805.001]
  • [Cites] Nat Rev Immunol. 2007 Dec;7(12):954-63 [17992179.001]
  • [Cites] J Immunol. 2007 Dec 15;179(12):8069-75 [18056347.001]
  • [Cites] Cell. 1986 Aug 29;46(5):705-16 [3091258.001]
  • [Cites] EMBO J. 1990 Oct;9(10):3137-44 [2209540.001]
  • [Cites] Cell. 1990 Nov 16;63(4):803-14 [2225078.001]
  • [Cites] Mol Cell Biol. 1992 Feb;12(2):674-84 [1732739.001]
  • [Cites] Am J Pathol. 1992 Nov;141(5):1237-46 [1443055.001]
  • [Cites] Dev Immunol. 1993;3(3):175-9 [8281032.001]
  • [Cites] Cell. 1995 Jan 27;80(2):321-30 [7834752.001]
  • [Cites] Cell. 1995 Jan 27;80(2):331-40 [7834753.001]
  • [Cites] Biotechniques. 1994 Nov;17(5):828-9 [7840956.001]
  • [Cites] Nature. 1995 Feb 9;373(6514):531-6 [7845467.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3640-50 [8670867.001]
  • [Cites] J Immunol. 1996 Nov 1;157(9):3974-9 [8892630.001]
  • [Cites] J Immunol. 1997 Mar 15;158(6):2558-66 [9058787.001]
  • [Cites] Science. 1997 Nov 14;278(5341):1309-12 [9360930.001]
  • [Cites] J Immunol. 1998 Apr 15;160(8):3666-72 [9558066.001]
  • [Cites] Immunity. 1998 Dec;9(6):839-47 [9881974.001]
  • [Cites] Semin Immunol. 1999 Feb;11(1):47-55 [9950751.001]
  • [Cites] J Immunol. 2005 Jan 1;174(1):21-5 [15611222.001]
  • [Cites] Curr Opin Immunol. 2005 Apr;17(2):137-43 [15766672.001]
  • [Cites] Biotechniques. 2005 May;38(5):702, 704, 706 [15945368.001]
  • [Cites] Leuk Lymphoma. 2005 Apr;46(4):483-95 [16019476.001]
  • [Cites] Trends Immunol. 2005 Oct;26(10):503-6 [16039157.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(22):10136-47 [16260626.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):209-20 [16354692.001]
  • [Cites] Immunol Rev. 2006 Feb;209:10-27 [16448531.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1554-9 [16261162.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Aug;17(4):281-93 [16793322.001]
  • [Cites] Biochem Pharmacol. 2006 Oct 30;72(9):1161-79 [16970925.001]
  • [Cites] Oncogene. 2006 Oct 30;25(51):6781-99 [17072328.001]
  • [Cites] Oncogene. 2006 Oct 30;25(51):6817-30 [17072330.001]
  • [Cites] Cell. 2007 Jan 26;128(2):369-81 [17254973.001]
  • (PMID = 18596915.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B p50 Subunit; 0 / Transcription Factor RelA; 147257-52-1 / Nfkb1 protein, mouse; 147337-75-5 / Transcription Factor RelB
  • [Other-IDs] NLM/ PMC2440518
  •  go-up   go-down


51. Tanimoto M: [Treatment strategies for acute lymphoblastic leukemia in adults]. Nihon Rinsho; 2007 Jan 28;65 Suppl 1:474-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment strategies for acute lymphoblastic leukemia in adults].
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Child. Humans. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17474450.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 3
  •  go-up   go-down


52. Xu B, Song X, Yip NC, Xiao P, Zhang Y, Wang W, Zhou S: Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia. Hematology; 2010 Apr;15(2):74-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia.
  • The interaction between Wilms tumor gene 1 (WT1) and the promoter region of the multidrug resistance-1 (MDR1) gene has been previously reported but the clinical significance of the coexpression of WT1 and MDR1 in acute lymphoblastic leukemia (ALL) is still largely unknown.
  • In this study, the expression levels of WT1 and MDR1 mRNA in 57 adult ALL patients were simultaneously detected using multiplex fluorescence real-time quantitative polymerase chain reaction.
  • The expression levels of WT1 and MDR1 in bone marrow samples of adult ALL patients were significantly higher than those in the normal samples (P<0.001), and in addition, the expression levels of WT1 and MDR1 mRNA were highly correlated (r(s)=0.404, P=0.002).
  • [MeSH-major] Biomarkers, Tumor / analysis. Bone Marrow / chemistry. Gene Expression Regulation, Leukemic. Genes, Wilms Tumor. Neoplasm Proteins / analysis. P-Glycoprotein / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. WT1 Proteins / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cohort Studies. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Resistance, Neoplasm / genetics. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. P-Glycoproteins. Prognosis. RNA, Messenger / biosynthesis. RNA, Neoplasm / biosynthesis. Remission Induction. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20423567.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / WT1 Proteins; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; CVAD protocol
  •  go-up   go-down


53. Roos-Weil D, Nguyen S, Uzunov M, Bories D, Chapiro E, Nguyen-Khac F, Vernant JP, Dhédin N: Therapy-related myelodysplastic syndrome after allogeneic BMT: successful treatment by donor lymphocyte infusions. Bone Marrow Transplant; 2010 Sep;45(9):1471-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adoptive Transfer. Bone Marrow Transplantation / adverse effects. Myelodysplastic Syndromes / etiology. Myelodysplastic Syndromes / therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Chromosome Aberrations. Chromosomes, Human, Pair 7. Humans. Male. Transplantation, Homologous. Young Adult


54. Styczyński J, Haus O: [Cytogenetics and in vitro drug resistance of acute leukemia in children and adults]. Postepy Hig Med Dosw (Online); 2006;60:527-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The translocation t(9;22) and the 11q23/MLL rearrangement are related to poor prognosis, while hyperdiploidy >50 chromosomes and the translocation t(12;21) are indicators of good prognosis in acute lymphoblastic leukemia (ALL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17060894.001).
  • [ISSN] 1732-2693
  • [Journal-full-title] Postepy higieny i medycyny doswiadczalnej (Online)
  • [ISO-abbreviation] Postepy Hig Med Dosw (Online)
  • [Language] POL
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Multidrug Resistance-Associated Proteins
  • [Number-of-references] 74
  •  go-up   go-down


55. Kivivuori SM, Siitonen S, Porkka K, Vettenranta K, Alitalo R, Saarinen-Pihkala U: Expression of vascular endothelial growth factor receptor 3 and Tie1 tyrosine kinase receptor on acute leukemia cells. Pediatr Blood Cancer; 2007 Apr;48(4):387-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PROCEDURE: We studied bone marrow samples from 73 patients with acute lymphoblastic (ALL) or myelogenous (AML) leukemia by using immunological methods.
  • RESULTS: Vascular endothelial growth factor receptor 3 expression was found in 15% of the samples, particularly in samples with pediatric lymphoblastic leukemias and monocytic AMLs.
  • Tie1 protein expression was found in 11% of the samples, all of which were from adult AML patients.
  • CONCLUSIONS: Our findings suggest that there are angiogenesis-related differences between pediatric and adult lymphoblastic leukemias as well as between lymphoid and myeloid leukemias.
  • [MeSH-major] Hematopoietic Stem Cells / enzymology. Leukemia, Myeloid / enzymology. Neoplastic Stem Cells / enzymology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Receptor, TIE-1 / analysis. Vascular Endothelial Growth Factor Receptor-3 / analysis
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Age Factors. Antigens, CD / analysis. Antigens, CD34 / analysis. Bone Marrow / pathology. Child. Child, Preschool. Female. Glycoproteins / analysis. Humans. Immunophenotyping. Infant. Leukemia, Monocytic, Acute / enzymology. Leukemia, Monocytic, Acute / pathology. Male. Neovascularization, Pathologic / enzymology. Neovascularization, Pathologic / pathology. Peptides / analysis

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685739.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Glycoproteins; 0 / Peptides; EC 2.7.10.1 / Receptor, TIE-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


56. Jabbour E, Koscielny S, Sebban C, Peslin N, Patte C, Gargi T, Biron P, Fermé C, Bourhis JH, Vantelon JM, Arnaud P, Ribrag V: High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL). Leukemia; 2006 May;20(5):814-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL).
  • The most appropriate treatment for lymphoblastic lymphomas (LL) remains uncertain.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / pathology. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Remission Induction. Survival Rate. Treatment Outcome


57. Dahlke J, Kröger N, Zabelina T, Ayuk F, Fehse N, Wolschke C, Waschke O, Schieder H, Renges H, Krüger W, Kruell A, Hinke A, Erttmann R, Kabisch H, Zander AR: Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. Bone Marrow Transplant; 2006 Jan;37(2):155-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation.
  • [MeSH-major] Donor Selection. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Child, Preschool. Cytomegalovirus Infections / etiology. Cytomegalovirus Infections / mortality. Disease-Free Survival. Female. Histocompatibility Testing. Humans. Infant. Male. Middle Aged. Recurrence. Retrospective Studies. Risk Factors. Sex Factors. Survival Rate. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284608.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


58. Thomas DA, Sarris AH, Cortes J, Faderl S, O'Brien S, Giles FJ, Garcia-Manero G, Rodriguez MA, Cabanillas F, Kantarjian H: Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer; 2006 Jan 1;106(1):120-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Salvage Therapy. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Drug Administration Schedule. Drug Resistance, Neoplasm. Humans. Liposomes. Middle Aged. Recurrence. Sphingomyelins

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • [ErratumIn] Cancer. 2006 Apr 1;106(7):1641
  • (PMID = 16331634.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Liposomes; 0 / Sphingomyelins; 5J49Q6B70F / Vincristine
  •  go-up   go-down


59. de Miguel D, García-Suárez J, Martín Y, Gil-Fernández JJ, Burgaleta C: Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs. Nephrol Dial Transplant; 2008 Dec;23(12):3762-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Brain Neoplasms / blood. Brain Neoplasms / drug therapy. Drug Interactions. Gemfibrozil / administration & dosage. Gemfibrozil / adverse effects. Humans. Lymphoma / blood. Lymphoma / drug therapy. Male. Middle Aged. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Retrospective Studies. Risk Factors

  • Hazardous Substances Data Bank. Gemfibrozil .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18779628.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Editorial; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q8X02027X3 / Gemfibrozil; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 17
  •  go-up   go-down


60. Fortune A, O'Leary H, Gilmore R, Chadwick N, Brennan L, Ní Chonghaile M, McCann SR, Browne PV, Conneally E, Vandenberghe E: T-lymphoblastic leukemia/lymphoma: a single center retrospective study of outcome. Leuk Lymphoma; 2010 Jun;51(6):1035-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-lymphoblastic leukemia/lymphoma: a single center retrospective study of outcome.
  • T-lymphoblastic leukemia/lymphoma (LBL and ALL) is a rare lymphoid malignancy typically presenting in adolescent and young adult males.
  • The successful use of intensified ALL protocols in patients <25 years with lymphoblastic malignancies without transplant prompted the Haematology Unit at St James's Hospital (SJH) to change practice in 2005 from transplanting in first complete remission (CR1) to treating patients <25 years with chemotherapy alone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20443674.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


61. Baum KJ, Ren R: Effect of Ras inhibition in hematopoiesis and BCR/ABL leukemogenesis. J Hematol Oncol; 2008 Jun 05;1:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we examined the effect of Ras inhibition by a dominant negative mutant of Ras, N17 H-Ras, in adult hematopoiesis and in BCR/ABL leukemogenesis using the mouse bone marrow transduction and transplantation approach.
  • Most BCR/ABL + N17 H-Ras mice eventually developed pro-B lymphoblastic leukemia/lymphoma (B-ALL).

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Mol Cell Biol. 2003 May;4(5):373-84 [12728271.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3938-46 [12907435.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):597-602 [14699048.001]
  • [Cites] J Clin Invest. 2004 Feb;113(4):528-38 [14966562.001]
  • [Cites] J Exp Med. 1976 Jun 1;143(6):1453-63 [178822.001]
  • [Cites] Annu Rev Biochem. 1987;56:779-827 [3304147.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4682-9 [2547513.001]
  • [Cites] J Exp Med. 1991 May 1;173(5):1213-25 [1827140.001]
  • [Cites] Cell. 1993 Oct 8;75(1):175-85 [8402896.001]
  • [Cites] EMBO J. 1994 Feb 15;13(4):764-73 [8112292.001]
  • [Cites] Ann N Y Acad Sci. 1994 May 31;716:327-30 [8024205.001]
  • [Cites] J Exp Med. 1995 Jan 1;181(1):307-13 [7807010.001]
  • [Cites] EMBO J. 1995 Jan 16;14(2):276-85 [7835338.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1709-13 [7878045.001]
  • [Cites] Oncogene. 1997 Sep 4;15(10):1151-9 [9294608.001]
  • [Cites] Genes Dev. 1997 Oct 1;11(19):2468-81 [9334313.001]
  • [Cites] EMBO J. 1997 Dec 1;16(23):7019-31 [9384581.001]
  • [Cites] Cell. 1998 May 29;93(5):841-50 [9630227.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3780-92 [9808572.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3829-40 [9808576.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):6918-28 [10490629.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):172-83 [15719031.001]
  • [Cites] Anal Biochem. 2000 Apr 10;280(1):20-8 [10805516.001]
  • [Cites] Blood. 2000 Jul 15;96(2):664-70 [10887132.001]
  • [Cites] Mol Cell. 2000 Sep;6(3):693-704 [11030348.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(3):840-53 [11154271.001]
  • [Cites] Mol Cell Biol. 2001 Mar;21(5):1444-52 [11238881.001]
  • [Cites] J Cell Sci. 2001 May;114(Pt 9):1603-8 [11309191.001]
  • [Cites] Oncogene. 2001 Dec 13;20(57):8236-48 [11781838.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2957-68 [11929787.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):479-92 [12124177.001]
  • [Cites] J Cell Biol. 2003 Jan 20;160(2):165-70 [12527752.001]
  • [Cites] Curr Opin Genet Dev. 2003 Feb;13(1):6-13 [12573429.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):4572-81 [12458225.001]
  • [Cites] Cancer Treat Res. 2003;115:189-208 [12613198.001]
  • (PMID = 18577264.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA068008; United States / NCI NIH HHS / CA / CA68008
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2438443
  •  go-up   go-down


62. Lu B, Li Q, Zou DH, Zhao YZ, Qi JY, Xu Y, Qui LG: [Analysis of clinical feature and treatment outcome in 42 patients with lymphoblastic lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2009 Jul;30(7):446-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of clinical feature and treatment outcome in 42 patients with lymphoblastic lymphoma].
  • OBJECTIVE: To investigate the clinical features and treatment outcomes of different regimens in Chinese patients with lymphoblastic lymphoma (LBL).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21678570.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


63. Bariakh EA, Kravchenko SK, Kremenetskaia AM, Zvonkov EE, Obukhova TN, Magomedova AU, Vorob'ev AI: [Clinical and epidemiological features of Burkitt's lymphoma]. Ter Arkh; 2009;81(7):47-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and epidemiological features of Burkitt's lymphoma].
  • AIM: To characterize clinical and epidemiological features of adult Berkitt's lymphoma (BL).
  • Murphy) was diagnosed in 5 patients, stage II--in 9, stage III--in 25, IV--in 14 patients, B-cell acute lymphoblastic leukemia (ALL) (L3)--in 19 patients.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Female. Humans. L-Lactate Dehydrogenase / metabolism. Male. Middle Aged. Neoplasm Staging. Sex Factors. Young Adult

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19708573.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


64. Okamoto R, Ogawa S, Nowak D, Kawamata N, Akagi T, Kato M, Sanada M, Weiss T, Haferlach C, Dugas M, Ruckert C, Haferlach T, Koeffler HP: Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia. Haematologica; 2010 Sep;95(9):1481-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia.
  • BACKGROUND: Differences in survival have been reported between pediatric and adult acute lymphoblastic leukemia.
  • The inferior prognosis in adult acute lymphoblastic leukemia is not fully understood but could be attributed, in part, to differences in genomic alterations found in adult as compared to in pediatric acute lymphoblastic leukemia.
  • DESIGN AND METHODS: We compared two different sets of high-density single nucleotide polymorphism array genotyping data from 75 new diagnostic adult and 399 previously published diagnostic pediatric acute lymphoblastic leukemia samples.
  • RESULTS: The high density single nucleotide polymorphism array analysis of 75 samples of adult acute lymphoblastic leukemia led to the identification of numerous cryptic and submicroscopic genomic lesions with a mean of 7.6 genomic alterations per sample.
  • The patterns and frequencies of lesions detected in the adult samples largely reproduced known genomic hallmarks detected in previous single nucleotide polymorphism-array studies of pediatric acute lymphoblastic leukemia, such as common deletions of 3p14.2 (FHIT), 5q33.3 (EBF), 6q, 9p21.3 (CDKN2A/B), 9p13.2 (PAX5), 13q14.2 (RB1) and 17q11.2 (NF1).
  • Some differences between adult and pediatric acute lymphoblastic leukemia were identified when the pediatric data set was partitioned into hyperdiploid and non-hyperdiploid cases and then compared to the nearly exclusively non-hyperdiploid adult samples.
  • In this analysis, adult samples had a higher rate of deletions of chromosome 17p (TP53) and duplication of 17q.
  • CONCLUSIONS: Our analysis of adult acute lymphoblastic leukemia cases led to the identification of new potential target lesions relevant for the pathogenesis of acute lymphoblastic leukemia.
  • However, no unequivocal pattern of submicroscopic genomic alterations was found to separate adult acute lymphoblastic leukemia from pediatric acute lymphoblastic leukemia.
  • Therefore, apart from different therapy regimen, differences of prognosis between adult and pediatric acute lymphoblastic leukemia are probably based on genetic subgroups according to cytogenetically detectable lesions but not focal genomic copy number microlesions.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2008 May 1;453(7191):110-4 [18408710.001]
  • [Cites] Leuk Lymphoma. 2008 Mar;49(3):477-87 [18297524.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11921-6 [18697940.001]
  • [Cites] Leukemia. 2009 Jan;23(1):134-43 [19020546.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):470-80 [19129520.001]
  • [Cites] Haematologica. 2009 Apr;94(4):518-27 [19278963.001]
  • [Cites] Int J Oncol. 2009 Jun;34(6):1603-12 [19424578.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8 [19470474.001]
  • [Cites] Blood. 2010 Apr 15;115(15):3089-97 [20160164.001]
  • [Cites] Haematologica. 2009 Feb;94(2):213-23 [19144660.001]
  • [Cites] Immunity. 2000 Dec;13(6):817-27 [11163197.001]
  • [Cites] J Exp Med. 2002 Mar 4;195(5):535-45 [11877477.001]
  • [Cites] J Cell Biol. 2004 Jan 19;164(2):175-84 [14734530.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] EMBO J. 1992 Apr;11(4):1663-70 [1373383.001]
  • [Cites] Mol Cell Biol. 1993 Sep;13(9):5513-23 [8355697.001]
  • [Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]
  • [Cites] Semin Cancer Biol. 2005 Jun;15(3):162-74 [15826831.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5561-70 [15994928.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6071-9 [16024607.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Dec;44(4):405-14 [16114034.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3673-80 [16585193.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3417-23 [17179230.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jul;46(7):661-9 [17420988.001]
  • [Cites] Am J Hum Genet. 2007 Jul;81(1):114-26 [17564968.001]
  • [Cites] Br J Haematol. 2007 Oct;139(2):269-74 [17897302.001]
  • [Cites] Nature. 2007 Sep 27;449(7161):473-7 [17851532.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6838-49 [17934490.001]
  • [Cites] Blood. 2008 Jan 15;111(2):776-84 [17890455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 6;105(18):6708-13 [18458336.001]
  • (PMID = 20435627.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA026038-31; United States / NCI NIH HHS / CA / R01 CA026038-32; United States / NCI NIH HHS / CA / CA026038-30A2; United States / NCI NIH HHS / CA / R01 CA026038; United States / NCI NIH HHS / CA / R01 CA026038-30A2
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2930948
  •  go-up   go-down


65. Al-Shakfa F, Dulucq S, Brukner I, Milacic I, Ansari M, Beaulieu P, Moghrabi A, Laverdière C, Sallan SE, Silverman LB, Neuberg D, Kutok JL, Sinnett D, Krajinovic M: DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia. Clin Cancer Res; 2009 Nov 15;15(22):6931-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia.
  • PURPOSE: Dihydrofolate reductase (DHFR) is the major target of methotrexate, a key component in childhood acute lymphoblastic leukemia (ALL) treatment.
  • [MeSH-major] DNA / genetics. Genetic Variation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Tetrahydrofolate Dehydrogenase / genetics
  • [MeSH-minor] Adult. Case-Control Studies. Child. Cohort Studies. Female. Haplotypes. Humans. Male. Methotrexate / pharmacology. Middle Aged. Pharmacogenetics. Polymorphism, Genetic. Promoter Regions, Genetic


66. Dickson BC, Chung CT, Patterson BJ, Riddell RH, Kamel-Reid S, Messner HA, Lipton JH: Precursor lymphoblastic lymphoma reoccurring as a donor-derived neoplasm: a case report and review of the literature. Arch Pathol Lab Med; 2008 Aug;132(8):1342-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor lymphoblastic lymphoma reoccurring as a donor-derived neoplasm: a case report and review of the literature.
  • Precursor lymphoblastic lymphoma is an uncommon neoplasm.
  • We report the case of a man who presented with precursor T lymphoblastic lymphoma and ultimately received an allogeneic bone marrow transplant from his human leukocyte antigen-identical sister.
  • We offer the report of a patient with an unusual lymphoblastic lymphoma who, after successful bone marrow transplantation, developed the same disease of donor cell origin; further, we offer a literature review on donor cell lymphoma.
  • [MeSH-major] Bone Marrow Transplantation / adverse effects. Kidney Neoplasms / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Adult. Amelogenin / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Mapping. Fatal Outcome. Humans. In Situ Hybridization, Fluorescence. Male. Siblings. Tissue Donors


67. Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, Ferry JA, Harris NL, Hasserjian RP, Zukerberg LR, Abramson JS, Hochberg EP, Lee H, Lee AI, Toomey CE, Sohani AR: B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol; 2010 Mar;34(3):327-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
  • B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements, also known as "double-hit" lymphomas (DHL), are rare neoplasms characterized by highly aggressive clinical behavior, complex karyotypes, and a spectrum of pathologic features overlapping with Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and B-lymphoblastic lymphoma/leukemia (B-LBL).
  • Six patients had a history of grade 1 to 2 follicular lymphoma; review of the prior biopsy specimens in 2 of 5 cases revealed blastoid morphology.
  • Twelve DHL cases (60%) were classified as B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL, 7 cases (35%) as DLBCL, not otherwise specified, and 1 case as B-LBL.
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Expression Regulation, Neoplastic. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Genes, Immunoglobulin Heavy Chain. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Child. Drug Resistance, Neoplasm. Female. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Karyotyping. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Predictive Value of Tests. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Terminology as Topic. Time Factors. Treatment Outcome. World Health Organization. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):525-34 [10757399.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1960-6 [11069032.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Nov;123(1):52-4 [11120335.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Apr 1;126(1):45-51 [11343778.001]
  • [Cites] Arch Pathol Lab Med. 2003 May;127(5):610-3 [12708908.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Arch Pathol Lab Med. 2004 Feb;128(2):210-3 [14736281.001]
  • [Cites] Int J Hematol. 2004 Jun;79(5):474-9 [15239399.001]
  • [Cites] Blood. 1983 Nov;62(5):1142-6 [6605167.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Nov;81(22):7166-70 [6334305.001]
  • [Cites] Am J Clin Pathol. 1986 May;85(5):636-40 [3486584.001]
  • [Cites] N Engl J Med. 1987 Nov 5;317(19):1185-9 [3657890.001]
  • [Cites] N Engl J Med. 1988 May 26;318(21):1373-8 [3285208.001]
  • [Cites] Oncogene. 1988 May;2(5):431-5 [3131717.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1454-9 [2509518.001]
  • [Cites] Genes Chromosomes Cancer. 1990 Jul;2(2):147-58 [2278969.001]
  • [Cites] Oncogene. 1991 Jan;6(1):145-8 [1992441.001]
  • [Cites] Leukemia. 1991 Jan;5(1):83-7 [1999960.001]
  • [Cites] Leukemia. 1991 Jun;5(6):473-8 [1711639.001]
  • [Cites] Hematol Oncol. 1991 Mar-Apr;9(2):63-78 [1869243.001]
  • [Cites] Ann Hematol. 1991 Nov;63(5):282-7 [1958753.001]
  • [Cites] Ann Hematol. 1992 Feb;64(2):101-4 [1554791.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Leukemia. 1994 Apr;8(4):560-3 [8152251.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jun;74(2):87-94 [8019967.001]
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):472-8 [7726146.001]
  • [Cites] Ann Oncol. 1998 Jan;9(1):55-61 [9541684.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3152-62 [9787151.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1558-67 [10334544.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):121-4 [15613866.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Aug;43(4):414-23 [15852472.001]
  • [Cites] Hum Pathol. 2005 May;36(5):571-5 [15948125.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1086-94 [16006805.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1490-6 [16224216.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2313-23 [16193090.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):25-33 [16258503.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Nov;171(1):52-6 [17074591.001]
  • [Cites] J Clin Pathol. 2007 Sep;60(9):1061-4 [17182663.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1335-42 [18024371.001]
  • [Cites] Am J Clin Pathol. 2008 Jan;129(1):157-66 [18089500.001]
  • [Cites] Curr Protoc Hum Genet. 2007 Jan;Chapter 8:Unit 8.8 [18428417.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1327-34 [18698080.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1593-607 [18753947.001]
  • [Cites] Br J Haematol. 2009 Mar;144(5):716-25 [19120369.001]
  • [Cites] Leukemia. 2009 Feb;23(2):225-34 [18923440.001]
  • [Cites] Leukemia. 2009 Apr;23(4):777-83 [19151788.001]
  • [Cites] Haematologica. 2009 Jul;94(7):935-43 [19535347.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2273-9 [19597184.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1297-301 [18024366.001]
  • (PMID = 20118770.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R37 CA076404; United States / NIGMS NIH HHS / GM / T32 GM074897; United States / NIGMS NIH HHS / GM / T32 GM074897-07
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc
  • [Other-IDs] NLM/ NIHMS305320; NLM/ PMC3152212
  •  go-up   go-down


68. Jiang NG, Zhu HL, Zeng TT, Su J, Zhang Y, Jia YQ: [Flow cytometric analysis of cerebrospinal fluid in the diagnosis of central nervous system leukemia]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Jul;41(4):664-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the 59 samples taken from patients with lymphocyte neoplasm, CD19 + blast cells were found in the CSF in 13 patients with B-cell lymphoblastic leukemia; CD7+ blast cells were found in 4 T-ALL cases; and monoclonal CD19+ cells were found in 6 other types of lymphoma cases.
  • [MeSH-major] Meningeal Neoplasms / cerebrospinal fluid. Meningeal Neoplasms / secondary. Precursor Cell Lymphoblastic Leukemia-Lymphoma / cerebrospinal fluid. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Flow Cytometry. Humans. Leukemia, Myeloid, Acute / cerebrospinal fluid. Male. Middle Aged. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20848792.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


69. Baldus CD, Thibaut J, Goekbuget N, Stroux A, Schlee C, Mossner M, Burmeister T, Schwartz S, Bloomfield CD, Hoelzer D, Thiel E, Hofmann WK: Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. Haematologica; 2009 Oct;94(10):1383-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia.
  • BACKGROUND: NOTCH1 mutations have been associated with a favorable outcome in pediatric acute T-lymphoblastic leukemia.
  • However, the results of studies on the prognostic significance of NOTCH1 mutations in adult T-lymphoblastic leukemia remain controversial.
  • DESIGN AND METHODS: Here we have investigated the prognostic impact of mutations in the NOTCH1 pathway, in particular, the NOTCH1 and FBXW7 genes, in a large cohort of adult patients with T-lymphoblastic leukemia (n=126).
  • CONCLUSIONS: NOTCH1 and FBXW7 mutations were not predictive of outcome in the overall cohort of adult patients with T-lymphoblastic leukemia, but there was a trend towards a favorable prognostic impact of NOTCH1-FBXW7 mutations in the small subgroup of patients with low-risk ERG/BAALC expression status.
  • Our findings further confirm the high frequency of NOTCH1 mutations in adult T-lymphoblastic leukemia.
  • [MeSH-major] Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Mutation / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptor, Notch1 / genetics. Ubiquitin-Protein Ligases / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate / trends. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Sep 21;276(38):35847-53 [11461910.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:162-92 [12446423.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1589-95 [12886247.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Immunity. 1999 May;10(5):547-58 [10367900.001]
  • [Cites] Semin Cell Dev Biol. 2005 Jun;16(3):323-33 [15840441.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1841-3 [16079893.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Leukemia. 2006 Mar;20(3):537-9 [16424867.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2540-3 [16282337.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):347-59 [16612405.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3043-9 [16707600.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1151-7 [16614245.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4714-20 [16954520.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:169-77 [17124057.001]
  • [Cites] Lancet. 2006 Nov 25;368(9550):1894-907 [17126723.001]
  • [Cites] Nat Rev Drug Discov. 2007 Feb;6(2):149-65 [17268486.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):1879-82 [17332312.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5611-6 [17575125.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3739-45 [17646667.001]
  • [Cites] Nat Med. 2007 Oct;13(10):1203-10 [17873882.001]
  • [Cites] J Exp Med. 2007 Nov 26;204(12):2875-88 [17984302.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6964-9 [18056171.001]
  • [Cites] Leukemia. 2008 Jan;22(1):124-31 [17928886.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1154-60 [18368072.001]
  • [Cites] Blood. 2008 Aug 1;112(3):733-40 [18411416.001]
  • [Cites] Nat Med. 2009 Jan;15(1):50-8 [19098907.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3918-24 [19109228.001]
  • [CommentIn] Haematologica. 2009 Oct;94(10):1338-40 [19794079.001]
  • (PMID = 19794083.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / Receptor, Notch1; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Other-IDs] NLM/ PMC2754954
  •  go-up   go-down


70. Gesundheit B, Resnick IB: Regurgitation of esophageal mucosa. Mayo Clin Proc; 2007 Aug;82(8):907
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Busulfan / adverse effects. Hematopoietic Stem Cell Transplantation. Humans. Male. Myeloablative Agonists / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / adverse effects. Vidarabine / adverse effects. Vidarabine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Nausea and Vomiting.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673057.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloablative Agonists; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
  •  go-up   go-down


71. Luczyński W, Krawczuk-Rybak M, Stasiak-Barmuta A: [Experimental and selected clinical aspects of active immunotherapy in leukemia]. Postepy Hig Med Dosw (Online); 2006;60:379-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The molecular mechanisms and selected clinical implications of different cancer vaccines used in pediatric and adult leukemias are discussed.
  • Cells of acute lymphoblastic leukemia and chronic lymphocytic leukemia can be induced into antigen-presenting cells with the CD40 ligation system.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885908.001).
  • [ISSN] 1732-2693
  • [Journal-full-title] Postepy higieny i medycyny doswiadczalnej (Online)
  • [ISO-abbreviation] Postepy Hig Med Dosw (Online)
  • [Language] POL
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Cancer Vaccines
  • [Number-of-references] 51
  •  go-up   go-down


72. Li YN, Zou DH, Gu M, Zhao YZ, Qi JY, Mi YC, Wang JX, Qiu LG: [Cytogenetic and prognostic analysis in adult patients with Philadelphia chromosome-positive and bcr-abl positive acute lymphoblastic leukaemia]. Zhonghua Xue Ye Xue Za Zhi; 2009 May;30(5):298-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytogenetic and prognostic analysis in adult patients with Philadelphia chromosome-positive and bcr-abl positive acute lymphoblastic leukaemia].
  • OBJECTIVE: To analyze the characteristics of cytogenetic aberration of adults with Philadelphia chromosome-positive (Ph+) and/or bcr-abl positive (bcr-abl+) acute lymphoblastic leukaemia (ALL), and investigate its influence on patients' outcomes.
  • METHOD: Retrospective analysis of 100 adult Ph+ ALL patients from January 1, 1996 to December 31, 2007 was carried out.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Chromosome Aberrations. Female. Humans. Immunophenotyping. Male. Middle Aged. Prognosis. Retrospective Studies. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19799123.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


73. Baumrucker SJ, Davis MP, Stolick M, Morris GM, Sheldon J: Sisters to the end: the rights of the mentally retarded to refuse treatment. Am J Hosp Palliat Care; 2005 Jan-Feb;22(1):61-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Intellectual Disability / complications. Legal Guardians. Mental Competency. Mentally Ill Persons. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Treatment Refusal
  • [MeSH-minor] Adult. Attitude of Health Personnel. Caregivers / standards. Female. Humans. Narration. Third-Party Consent

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15736609.001).
  • [ISSN] 1049-9091
  • [Journal-full-title] The American journal of hospice & palliative care
  • [ISO-abbreviation] Am J Hosp Palliat Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] KIE/ 128085; NRCBL/ VF 8.3.3
  • [Keywords] KIE ; Professional Patient Relationship
  • [General-notes] KIE/ 6 refs.; KIE/ KIE Bib: treatment refusal/mentally disabled
  •  go-up   go-down


74. Lee WS, Kim TY: Platelet indices are not suitable for screening of leukemia. J Pediatr Hematol Oncol; 2010 Apr;32(3):251
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Blood Platelets / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Platelet Count. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Pediatr Hematol Oncol. 2008 Dec;30(12):953-5 [19131790.001]
  • (PMID = 20048686.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Comparative Study; Letter
  • [Publication-country] United States
  •  go-up   go-down


75. Santagata S, van Horne C, Sallan SE, McLaughlin ME, Ramakrishna NR: Post-irradiation meningioma with sarcoidosis. J Neurooncol; 2007 May;82(3):271-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Humans. Magnetic Resonance Imaging. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Seizures / etiology


76. Feusner J, Gregory JJ Jr: Update on the management of pediatric acute promyelocytic leukemia. Clin Adv Hematol Oncol; 2006 Nov;4(11):854-5; author reply 855-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Child. Child, Preschool. Female. Hemorrhage / blood. Hemorrhage / etiology. Hemorrhage / mortality. Hemorrhage / therapy. Humans. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Clin Adv Hematol Oncol. 2006 Apr;4(4):263-5 [16728936.001]
  • (PMID = 17193721.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


77. Reutenauer S, Albucher JF, Pariente J, Dumas H, Milioto O, Attal M, Recher C, Huguet F: Posterior reversible encephalopathy syndrome: two cases in young adults with acute lymphoblastic leukemia. Leuk Res; 2009 Jun;33(6):e1-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posterior reversible encephalopathy syndrome: two cases in young adults with acute lymphoblastic leukemia.
  • [MeSH-major] Brain Diseases / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Adult. Female. Humans. Male


78. Marchese VG, Connolly BH, Able C, Booten AR, Bowen P, Porter BM, Rai SN, Hancock ML, Pui CH, Howard S, Neel MD, Kaste SC: Relationships among severity of osteonecrosis, pain, range of motion, and functional mobility in children, adolescents, and young adults with acute lymphoblastic leukemia. Phys Ther; 2008 Mar;88(3):341-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationships among severity of osteonecrosis, pain, range of motion, and functional mobility in children, adolescents, and young adults with acute lymphoblastic leukemia.
  • BACKGROUND AND PURPOSE: Up to 38% of children receiving treatment for acute lymphoblastic leukemia (ALL) develop osteonecrosis, often without symptoms.
  • [MeSH-major] Arthralgia / physiopathology. Osteonecrosis / physiopathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Range of Motion, Articular / physiology. Severity of Illness Index
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / adverse effects. Arthrometry, Articular. Child. Child, Preschool. Exercise Test. Female. Glucocorticoids / adverse effects. Hip Joint / pathology. Hip Joint / physiopathology. Humans. Knee Joint / pathology. Knee Joint / physiopathology. Magnetic Resonance Imaging. Male. Pain Measurement

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18202079.001).
  • [ISSN] 0031-9023
  • [Journal-full-title] Physical therapy
  • [ISO-abbreviation] Phys Ther
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2U54CA055727-12; United States / NCI NIH HHS / CA / P01 CA-20180; United States / NCI NIH HHS / CA / P30 CA-21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids
  •  go-up   go-down


79. Thoms KM, Baesecke J, Emmert B, Hermann J, Roedling T, Laspe P, Leibeling D, Truemper L, Emmert S: Functional DNA repair system analysis in haematopoietic progenitor cells using host cell reactivation. Scand J Clin Lab Invest; 2007;67(6):580-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kasumi-1 AML tells exhibited a reduced DSB repair capacity compared to AG10107 and GM03715 normal lymphocytes as well as CEM acute T-cell lymphoblastic leukaemia cells (6.4 +/- 0.8% vs. 10.8 +/- 0.7%, 27.3 +/- 1.1% and 20.5 +/- 1.6%, respectively).
  • [MeSH-minor] Cells, Cultured. DNA Breaks, Double-Stranded / radiation effects. DNA Damage. Enzyme Activation. Female. Genetic Techniques. HL-60 Cells. Humans. Leukemia, Monocytic, Acute / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Microsatellite Instability / radiation effects. Plasmids / genetics. Radiation Injuries / genetics. Transfection. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852814.001).
  • [ISSN] 0036-5513
  • [Journal-full-title] Scandinavian journal of clinical and laboratory investigation
  • [ISO-abbreviation] Scand. J. Clin. Lab. Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 9007-49-2 / DNA; EC 1.13.12.- / Luciferases
  •  go-up   go-down


80. Zhou RQ, Gong YP, Zheng BH, Yang X: [Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep;41(5):789-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia].
  • METHODS: Primary leukemia cells were isolated from bone marrow of adult acute leukemia patients using Ficoll liquid, then the primary leukemia cells were treated with different concentration of these two drugs (Bor 5, 10, 20, 50 nmol/L, DNR 50, 100, 200, 500 nmol/L, and Bor 5, 10 nmol/L combined with DNR 50, 100, 200, 500 nmol/L respectively ).
  • CONCLUSION: Bor combined with DNR shows synergetic effect in promoting the apoptosis of adult acute leukemia primary cells as well as inhibitory effect on the proliferation of leukemia cells.
  • [MeSH-major] Apoptosis / drug effects. Boronic Acids / pharmacology. Daunorubicin / pharmacology. Leukemia, Myeloid, Acute / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Pyrazines / pharmacology
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / pharmacology. Antineoplastic Agents / pharmacology. Bortezomib. Drug Synergism. Female. Humans. Male. Middle Aged. Tumor Cells, Cultured. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21302442.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


81. Yoo JH, Choi SM, Lee DG, Choi JH, Shin WS, Min WS, Kim CC: Prognostic factors influencing infection-related mortality in patients with acute leukemia in Korea. J Korean Med Sci; 2005 Feb;20(1):31-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Bacterial Infections / mortality. Leukemia, Myeloid, Acute / microbiology. Leukemia, Myeloid, Acute / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / microbiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Cause of Death. Female. Humans. Korea. Leukemia. Male. Middle Aged. Morbidity. Multivariate Analysis. Mycoses / complications. Mycoses / mortality. Neutropenia. Pneumonia / complications. Pneumonia / mortality. Prognosis. Retrospective Studies. Sepsis / complications. Sepsis / mortality. Survival Rate

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Microbiol Infect Dis. 1999 Jul;34(3):221-7 [10403102.001]
  • [Cites] Clin Infect Dis. 1998 Apr;26(4):781-803; quiz 804-5 [9564455.001]
  • [Cites] Clin Infect Dis. 1999 Sep;29(3):490-4 [10530434.001]
  • [Cites] Arch Intern Med. 2000 Feb 28;160(4):501-9 [10695690.001]
  • [Cites] Med Oncol. 2000 May;17(2):111-6 [10871816.001]
  • [Cites] Infection. 2000 Nov-Dec;28(6):367-73 [11139156.001]
  • [Cites] Infect Dis Clin North Am. 2001 Jun;15(2):457-82 [11447706.001]
  • [Cites] Clin Infect Dis. 2002 Jan 1;34(1):7-14 [11731939.001]
  • [Cites] Clin Infect Dis. 2002 Mar 15;34(6):730-51 [11850858.001]
  • [Cites] Ann Hematol. 2003 Oct;82 Suppl 2:S105-17 [13680173.001]
  • [Cites] Bone Marrow Transplant. 2004 Sep;34(6):497-504 [15286689.001]
  • [Cites] Ann Intern Med. 1966 Feb;64(2):328-40 [5216294.001]
  • [Cites] Ann Intern Med. 1972 Nov;77(5):707-14 [4628214.001]
  • [Cites] Am Rev Respir Dis. 1976 Sep;114(3):593-627 [184728.001]
  • [Cites] Arch Intern Med. 1985 Sep;145(9):1621-9 [3927867.001]
  • [Cites] Am J Med. 1986 May 30;80(5C):13-20 [3521270.001]
  • [Cites] Clin Infect Dis. 1994 Mar;18(3):390-4 [8011821.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):791-8 [8616774.001]
  • [Cites] Infect Dis Clin North Am. 1996 Dec;10(4):777-96 [8958168.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1):132-40 [9045299.001]
  • [Cites] Clin Infect Dis. 1997 Aug;25(2):247-59 [9332520.001]
  • [Cites] N Engl J Med. 1999 Sep 16;341(12):893-900 [10486422.001]
  • (PMID = 15716598.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2808571
  •  go-up   go-down


82. Chang PY, Draheim K, Kelliher MA, Miyamoto S: NFKB1 is a direct target of the TAL1 oncoprotein in human T leukemia cells. Cancer Res; 2006 Jun 15;66(12):6008-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recently showed that a subset of human T acute lymphoblastic leukemia (T-ALL) cell lines expresses low basal levels of p50, a nuclear factor-kappaB (NF-kappaB)/Rel family member, resulting in their capacity to activate the atypical p65:cRel complex rather than the classic p50:p65 dimer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16778171.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096899; United States / NCI NIH HHS / CA / R01-CA077474; United States / NCI NIH HHS / CA / R01-CA081065
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / NF-kappa B p50 Subunit; 0 / NFKB1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Transcription Factor RelA; 135471-20-4 / TAL1 protein, human; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


83. Rea D, Legros L, Raffoux E, Thomas X, Turlure P, Maury S, Dupriez B, Pigneux A, Choufi B, Reman O, Stéphane D, Royer B, Vigier M, Ojeda-Uribe M, Recher C, Dombret H, Huguet F, Rousselot P, Intergroupe Français des Leucémies Myéloïdes Chronique, Group for Research in Adult Acute Lymphoblastic Leukemia: High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia; 2006 Mar;20(3):400-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.
  • Thirty-one patients (18 relapsing or refractory Ph+ acute lymphoblastic leukemias and 13 lymphoid blast crisis chronic myelogenous leukemias) were enrolled.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blast Crisis / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


84. Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O'Brien S, Cortes J, Verstovsek S, Browning ML, Faderl S: Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer; 2006 Jun 15;106(12):2645-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because CD52 also is expressed on acute leukemic blasts, the authors investigated the safety and efficacy of alemtuzumab in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antigens, CD / immunology. Antigens, Neoplasm / immunology. Glycoproteins / immunology. Leukemia, Myeloid / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Antibodies, Monoclonal, Humanized. Bacteremia / diagnosis. Bacteremia / etiology. Bone Marrow / drug effects. Bone Marrow / pathology. Disease Progression. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Female. Fungemia / diagnosis. Fungemia / etiology. Humans. Male. Middle Aged. Pneumonia / diagnosis. Pneumonia / etiology. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16688777.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  •  go-up   go-down


85. de Oliveira FM, Falcão RP, de Figueiredo Pontes LL, Simões BP, Tone LG: Insertion (15;14)(q22;q13q32) in a case of Ph+ ALL. Cancer Genet Cytogenet; 2008 Aug;185(1):65-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 15. Mutagenesis, Insertional. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male. Spectral Karyotyping

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656700.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


86. Takada S, Yamashita Y, Berezikov E, Hatanaka H, Fujiwara SI, Kurashina K, Watanabe H, Enomoto M, Soda M, Choi YL, Mano H: MicroRNA expression profiles of human leukemias. Leukemia; 2008 Jun;22(6):1274-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. MicroRNAs / genetics. Myelodysplastic Syndromes / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / metabolism. Base Sequence. Cluster Analysis. Female. Gene Expression / physiology. Humans. Male. Middle Aged. Molecular Sequence Data. Sequence Homology, Nucleic Acid

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17989710.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / MicroRNAs
  •  go-up   go-down


87. Bárdi E, Bobok I, V Oláh A, Kappelmayer J, Kiss C: Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer. Pathol Oncol Res; 2007;13(3):249-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Anthracyclines / adverse effects. Antibiotics, Antineoplastic / adverse effects. Kidney Diseases / chemically induced. Lymphoma, Non-Hodgkin / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Acetylglucosaminidase / urine. Adolescent. Adult. Albuminuria / chemically induced. Albuminuria / metabolism. Albuminuria / prevention & control. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Creatinine / blood. Daunorubicin / adverse effects. Daunorubicin / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Epirubicin / adverse effects. Epirubicin / therapeutic use. Female. Humans. Idarubicin / adverse effects. Idarubicin / therapeutic use. Infant. Kidney Tubules, Proximal / drug effects. Male. Razoxane / therapeutic use. Retrospective Studies

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1995 Feb;13(2):359-72 [7844597.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(4):329-34 [10755322.001]
  • [Cites] Pediatr Blood Cancer. 2004 Nov;43(6):668-73 [15390293.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2705-13 [11352963.001]
  • [Cites] Med Pediatr Oncol. 2002 Jul;39(1):18-24 [12116074.001]
  • [Cites] Nihon Sanka Fujinka Gakkai Zasshi. 1985 Jun;37(6):888-96 [4040542.001]
  • [Cites] Med Pediatr Oncol. 1991;19(3):199-203 [1850817.001]
  • [Cites] Cancer Treat Rep. 1982 Feb;66(2):395-7 [7055822.001]
  • [Cites] Pediatr Nephrol. 2004 Oct;19(10):1145-7 [15258844.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3333-55 [10506637.001]
  • [Cites] Bratisl Lek Listy. 2001;102(8):357-60 [11763664.001]
  • [Cites] Pediatr Hematol Oncol. 1994 Nov-Dec;11(6):613-23 [7857784.001]
  • [Cites] Ann Clin Biochem. 1994 Jan;31 ( Pt 1):87-8 [8154857.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):334-41 [12525527.001]
  • [Cites] Cancer. 1992 Nov 15;70(10):2557-67 [1482503.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3736-44 [10577845.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Mar;25(3):209-14 [12621239.001]
  • (PMID = 17922055.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin; 5AR83PR647 / Razoxane; 80168379AG / Doxorubicin; AYI8EX34EU / Creatinine; EC 3.2.1.52 / Acetylglucosaminidase; ZRP63D75JW / Idarubicin; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


88. Thachil J: Reduced elimination of Methotrexate in an adult with trisomy 21 and acute lymphoblastic leukaemia. Leuk Res; 2007 Oct;31(10):1452-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced elimination of Methotrexate in an adult with trisomy 21 and acute lymphoblastic leukaemia.
  • [MeSH-major] Antimetabolites, Antineoplastic / blood. Down Syndrome / metabolism. Methotrexate / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Female. Humans

  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17178159.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


89. Gross SA, Zhu X, Bao L, Ryder J, Le A, Chen Y, Wang XQ, Irons RD: A prospective study of 728 cases of non-Hodgkin lymphoma from a single laboratory in Shanghai, China. Int J Hematol; 2008 Sep;88(2):165-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of 728 cases of non-Hodgkin lymphoma from a single laboratory in Shanghai, China.
  • The frequency of non-Hodgkin lymphoma was 87.6% (n = 728) and Hodgkin lymphoma was 12.4% (n = 103).
  • The most prevalent NHL subtypes diagnosed using WHO criteria were diffuse large B cell lymphoma (DLBCL), precursor B lymphoblastic leukemia/lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
  • Consistent with previous reports, our findings indicate a decrease in the frequency of follicular lymphoma and an increase in T cell neoplasms compared to the West.
  • Precursor T lymphoblastic leukemia/lymphoma, anaplastic large T cell lymphoma, aggressive NK cell leukemia, angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma were prominent subtypes of T cell NHL.
  • [MeSH-major] Asian Continental Ancestry Group / statistics & numerical data. Lymphoma, Non-Hodgkin / classification. Lymphoma, Non-Hodgkin / ethnology
  • [MeSH-minor] Adult. China / epidemiology. DNA, Neoplasm / analysis. Humans. In Situ Hybridization, Fluorescence. Prevalence. Prospective Studies. Urban Population / statistics & numerical data. World Health Organization

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1984 Aug 15;34(2):143-8 [6381328.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1091-6 [15205204.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1813-9 [8859197.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1151-68 [7858247.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Cancer Lett. 1999 Jan 8;135(1):73-81 [10077224.001]
  • [Cites] Cancer. 1994 Jul 1;74(1):174-81 [8004573.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Oct;5(5):983-1001 [1938764.001]
  • [Cites] Int J Hematol. 2007 Jan;85(1):18-25 [17261497.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1360-4 [17326056.001]
  • [Cites] Hum Pathol. 1987 Sep;18(9):924-8 [3497862.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Dec;13(4):323-32 [16280661.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1586-92 [11013375.001]
  • [Cites] Br J Haematol. 1999 Nov;107(2):353-6 [10583224.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2005 Jan;34(1):22-7 [15796877.001]
  • [Cites] Pathol Int. 2002 Jan;52(1):1-12 [11940200.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):114-41; discussion 200-2 [12196212.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):806-12 [9708949.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:1-39 [17405121.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • (PMID = 18648906.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


90. Borriello A, Locasciulli A, Bianco AM, Criscuolo M, Conti V, Grammatico P, Cappellacci S, Zatterale A, Morgese F, Cucciolla V, Delia D, Della Ragione F, Savoia A: A novel Leu153Ser mutation of the Fanconi anemia FANCD2 gene is associated with severe chemotherapy toxicity in a pediatric T-cell acute lymphoblastic leukemia. Leukemia; 2007 Jan;21(1):72-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel Leu153Ser mutation of the Fanconi anemia FANCD2 gene is associated with severe chemotherapy toxicity in a pediatric T-cell acute lymphoblastic leukemia.
  • We report the clinical and molecular features of a patient initially identified as a potential FA case only because of chemotherapy toxicity during the treatment of a T-lineage acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Fanconi Anemia Complementation Group D2 Protein / genetics. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / genetics. Mutation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Fanconi Anemia.
  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17096012.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] Italy / Telethon / / TGM06S01
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / FANCD2 protein, human; 0 / Fanconi Anemia Complementation Group D2 Protein; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


91. Fang B, Song Y, Zhao RC, Han Q, Cao Y: Treatment of resistant pure red cell aplasia after major ABO-incompatible bone marrow transplantation with human adipose tissue-derived mesenchymal stem cells. Am J Hematol; 2007 Aug;82(8):772-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] ABO Blood-Group System. Adult. Blood Group Incompatibility. Female. Humans. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery


92. Gaynon PS: Treatment adherence and 6-mercaptopurine metabolites. Pediatr Blood Cancer; 2006 Feb;46(2):120-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] 6-Mercaptopurine / pharmacokinetics. Antimetabolites, Antineoplastic / pharmacokinetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Cluster Analysis. Dose-Response Relationship, Drug. Female. Humans. Male. Multivariate Analysis. Recurrence. Risk Factors. Treatment Failure

  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Pediatr Blood Cancer. 2006 Feb;46(2):187-92 [16086421.001]
  • (PMID = 16200555.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; E7WED276I5 / 6-Mercaptopurine
  •  go-up   go-down


93. Steiner M, Attarbaschi A, König M, Gadner H, Haas OA, Mann G: Equal frequency of TEL/AML1+ acute lymphoblastic leukemia in children with and without Down syndrome. Pediatr Hematol Oncol; 2005 Jan-Feb;22(1):11-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Equal frequency of TEL/AML1+ acute lymphoblastic leukemia in children with and without Down syndrome.
  • Constitutional trisomy 21 is the most prominent predisposing factor to childhood leukemia, whereas the t(12;21)(p13;q22) with its molecular genetic counterpart, the TEL/AML1 fusion gene, is the most common acquired chromosomal rearrangement in childhood B-cell precursor (BCP) acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Down Syndrome / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Austria / epidemiology. Child, Preschool. Chromosomes, Human, Pair 21 / genetics. Core Binding Factor Alpha 2 Subunit. Female. Humans. In Situ Hybridization, Fluorescence. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RepublishedIn] Pediatr Hematol Oncol. 2005 Apr-May;22(3):229-34 [16020107.001]
  • (PMID = 15770827.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


94. Yang HK, Yu HG: Acute lymphoblastic leukemia manifesting as acute Vogt-Koyanagi-Harada disease. Korean J Ophthalmol; 2009 Dec;23(4):325-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia manifesting as acute Vogt-Koyanagi-Harada disease.
  • We describe a case of bilateral exudative retinal detachment associated with prodromal symptoms simulating the presentation of acute Vogt-Koyanagi-Harada disease that was eventually diagnosed as acute lymphoblastic leukemia.
  • However, complete blood cell count showed a marked increase in the number of white blood cells and bone marrow examination revealed precursor B cell lymphoblastic leukemia.
  • Bilateral exudative retinal detachment associated with neurologic and auditory abnormalities may be a presenting sign of acute lymphoblastic leukemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Retinal Detachment / etiology. Uveomeningoencephalitic Syndrome / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Fluorescein Angiography. Follow-Up Studies. Fundus Oculi. Humans. Male. Tomography, Optical Coherence. Visual Acuity

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Retinal Detachment.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kaohsiung J Med Sci. 2001 Mar;17(3):150-5 [11486647.001]
  • [Cites] Curr Opin Neurol. 2002 Dec;15(6):691-9 [12447107.001]
  • [Cites] Leuk Res. 2003 Jun;27(6):557-9 [12648516.001]
  • [Cites] Am J Ophthalmol. 1979 May;87(5):698-702 [443342.001]
  • [Cites] Ann Ophthalmol. 1979 Dec;11(12):1867-72 [299244.001]
  • [Cites] Am J Ophthalmol. 1987 Oct 15;104(4):364-72 [3661646.001]
  • [Cites] Retina. 1989;9(2):110-4 [2772418.001]
  • [Cites] Am J Ophthalmol. 1990 Apr 15;109(4):436-44 [2330946.001]
  • [Cites] Am J Ophthalmol. 1996 Jul;122(1):58-66 [8659599.001]
  • [Cites] Surv Ophthalmol. 1964 Oct;9:467-73 [14199728.001]
  • [Cites] Eur J Ophthalmol. 2005 Mar-Apr;15(2):284-6 [15812775.001]
  • [Cites] Retina. 2006 Jul-Aug;26(6):710-2 [16829822.001]
  • [Cites] Am J Ophthalmol. 2007 Aug;144(2):260-5 [17533104.001]
  • [Cites] Curr Eye Res. 2008 Jul;33(7):517-23 [18600484.001]
  • [Cites] Retina. 2003 Dec;23(6):820-46; quiz 895-6 [14707834.001]
  • [Cites] Acta Haematol. 2000;104(1):46-9 [11111123.001]
  • [Cites] Am J Ophthalmol. 2001 May;131(5):647-52 [11336942.001]
  • [Cites] Retina. 2001;21(3):237-42 [11421013.001]
  • (PMID = 20046700.001).
  • [ISSN] 2092-9382
  • [Journal-full-title] Korean journal of ophthalmology : KJO
  • [ISO-abbreviation] Korean J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2789964
  • [Keywords] NOTNLM ; Exudative retinal detachment / Leukemia / Vogt-Koyanagi-Harada disease
  •  go-up   go-down


95. Stapleton GE, Stapleton SL, Martinez A, Ayres NA, Kovalchin JP, Bezold LI, Pignatelli R, Eidem BW: Evaluation of longitudinal ventricular function with tissue Doppler echocardiography in children treated with anthracyclines. J Am Soc Echocardiogr; 2007 May;20(5):492-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Anthracyclines / therapeutic use. Echocardiography, Doppler / methods. Hodgkin Disease / drug therapy. Neuroblastoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Ventricular Dysfunction, Left / ultrasonography. Ventricular Function, Left / physiology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Infant. Male. Myocardial Contraction / drug effects. Myocardial Contraction / physiology. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Soc Echocardiogr. 2008 Dec;21(12):1290-2 [19041570.001]
  • (PMID = 17484989.001).
  • [ISSN] 1097-6795
  • [Journal-full-title] Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
  • [ISO-abbreviation] J Am Soc Echocardiogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines
  •  go-up   go-down


96. Lightfoot TJ, Roman E, Smith MT, Skibola CF: Acute lymphoblastic leukaemia in children - is there a role for MTHFR? Br J Haematol; 2010 Jun;149(5):797-8; author reply 799-800
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukaemia in children - is there a role for MTHFR?
  • [MeSH-major] Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Age Factors. Child. Genetic Predisposition to Disease. Humans. Meta-Analysis as Topic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2007 Apr;48(4):786-92 [17454638.001]
  • [Cites] Br J Haematol. 2010 Jan;148(1):3-14 [19775302.001]
  • [Cites] Blood. 2010 May 13;115(19):3923-9 [20101025.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1956-63 [17035405.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12810-5 [10536004.001]
  • [Cites] Eur J Epidemiol. 2006;21(7):501-10 [16897583.001]
  • [Cites] Blood. 2004 Jan 1;103(1):252-7 [12958073.001]
  • [Cites] Haematologica. 2004 Feb;89(2):139-44 [15003888.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):787-94 [15159311.001]
  • [Cites] Am J Hematol. 2003 Jul;73(3):154-60 [12827651.001]
  • [CommentOn] Br J Haematol. 2010 Jan;148(1):3-14 [19775302.001]
  • (PMID = 20148884.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P42 ES004705; United States / NCI NIH HHS / CA / R01 CA104682
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  • [Other-IDs] NLM/ NIHMS453668; NLM/ PMC3876734
  •  go-up   go-down


97. Holowiecka-Goral A, Hołowiecki J, Giebel S, Stella-Holowiecka B, Krawczyk-Kulis M, Kos K, Lehmann-Kopydłowska A, Dudzinski M, Hałasz M, Preisner W, Cioch M, Piszcz J: Liposomal cytarabine in advanced-stage acute lymphoblastic leukemia and aggressive lymphoma with central nervous system involvement: experience of the Polish Acute Leukemia Group. Leuk Lymphoma; 2009 Mar;50(3):478-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposomal cytarabine in advanced-stage acute lymphoblastic leukemia and aggressive lymphoma with central nervous system involvement: experience of the Polish Acute Leukemia Group.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Cytarabine / administration & dosage. Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Drug Carriers. Female. Humans. Liposomes. Male. Middle Aged. Poland. Remission Induction. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19294561.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Liposomes; 04079A1RDZ / Cytarabine
  •  go-up   go-down


98. Barry E, DeAngelo DJ, Neuberg D, Stevenson K, Loh ML, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin M, Cohen HJ, Sallan SE, Silverman LB: Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol; 2007 Mar 1;25(7):813-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
  • PURPOSE: Historically, adolescents with acute lymphoblastic leukemia (ALL) have had inferior outcomes when compared with younger children.
  • However, the 5-year EFS for older adolescents was 78% +/- 6%, which is superior to published outcomes for similarly aged patients treated with other pediatric and adult ALL regimens.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327603.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 68484
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


99. Ji Y, Zhang W, Wang J, Gu L: mRNA expression of the XAGE-1 gene in human acute leukemia. Int J Hematol; 2010 Mar;91(2):209-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antigens, Neoplasm / genetics. Gene Expression Regulation, Leukemic. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Marrow / physiology. Female. Humans. Male. Middle Aged. Phenotype. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Immun. 2007 Oct 19;7:16 [17944437.001]
  • [Cites] Br J Cancer. 1999 Dec;81(7):1162-4 [10584877.001]
  • [Cites] Leuk Res. 2007 Jan;31(1):1-3 [17083973.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1218-25 [16929165.001]
  • [Cites] Cancer Immun. 2008 Aug 28;8:13 [18752338.001]
  • [Cites] Lung Cancer. 2003 Oct;42(1):23-33 [14512184.001]
  • [Cites] Microbiol Immunol. 2005;49(5):471-6 [15905609.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2740-8 [18451240.001]
  • [Cites] Int J Cancer. 1998 Oct 29;78(3):387-9 [9766577.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):713-20 [11531257.001]
  • [Cites] Br J Haematol. 2007 Mar;136(6):769-76 [17223912.001]
  • [Cites] Int J Oncol. 2007 Apr;30(4):835-40 [17332921.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] Mol Cancer Ther. 2002 May;1(7):441-50 [12479262.001]
  • [Cites] Immunol Rev. 2002 Oct;188:22-32 [12445278.001]
  • [Cites] Microbiol Immunol. 2007;51(8):755-62 [17704638.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5496-503 [16061866.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):361-9 [11992404.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1445-8 [10197611.001]
  • (PMID = 20178013.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / RNA, Messenger; 0 / XAGE1A protein, human
  •  go-up   go-down


100. Song HH, Chen BA, Ding JH, Sun XM, Gao C, Sun YY, Wang J, Cheng J, Zhao G: [Effect of hematopoietic stem cell transplantation in malignant hematologic disease of lymphatic system]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct;14(5):945-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Through observing 8 patients with non-Hodgkin's lymphoma (NHL) and 3 patients with lymphoblastic leukemia, who received auto or allo-HSCT after chemotherapy, the hematopoietic reconstitution, complication and survival time were evaluated.
  • From 4 cases received allo-PBSCT, one patient with NHL (NK cell) was died at 79 days later, one patient with chronic lymphoblastic leukemia was surviving, another 2 cases of acute lymphoblastic leukemia were dead at 17 months and 54 days respectively after allo-PBSCT.

  • Genetic Alliance. consumer health - Lymphatic Disease.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17096894.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down






Advertisement